JOURNAL CONTENT
CONTACT

Submission of the manuscript is online via e-mail
ecgarticle@gmail.com or
cholerez@mail.ru

Tel: +7 903 250 5288

Editorial Correspondence e-mail
gastrossr@gmail.com


Publishing, Subscriptions, Sales and Advertising, Correspondence e-mail
journal@cniig.ru

Tel: +7 917 561 9505

THE RULES OF SUBMITTING AN ARTICLE

READ

Scimago Journal & Country Rank

SCImago Journal & Country Rank

№ 05 (129) 2016

  • Уважаемые коллеги !
    У вас в руках свежий номер журнала «Экспериментальная и клиническая гастроэнтерология», посвященный актуальным и нерешенным вопросам в гастроэнтерологии и адресованный широкому кругу врачей разных специальностей. Открывает номер передовая статья в которой описаны оригинальные исследования по проблемам коморбидности у современных пациентов. Так, статья Ткаченко Е. И., Орешко Л. С., Соловьева Е. А., Шабанова А. А., Журавлева М. С. посвящена ассоциации наиболее частых, генетически детерминированных заболеваний: целиакии и дисплазии соединительной ткани В разделе «клиническая гастроэнтерология» представлены: «Роль микробиоты кишечника в развитии ожирения в возрастном аспекте» (авторы М. Ю. Щербакова, А. В. Власова, Т. А. Роживанова), статья продолжает серию публикаций, о роли микробиоты при различных соматических заболеваниях. В актуальном обзоре содержатся сведения о популяционном и видом составе микроорганизмов у пациентов различного возраста, страдающих ожирением, представлен анализ публикаций о механизмах развития метаболического синдрома с учетом вклада кишечника и его значимой составляющей — микробиоты в каскад патологических реакций, приводящих к развитию ожирения. Приводятся данные о результатах комплексного лечения ожирения с включением пробиотиков. Работа Гриценко Т. А., Давыдкина И. Л., Осадчук А. М., Косталановой Ю. В. об особенностях ГЭРБ у пациентов с гемобластозами, получающих полихимиотерапию. Авторы отметили рефрактерность ГЭРБ к терапии ИПП, связанную с нарушениями процессов пролиферации и дифференцировки эпителоцитов на фоне агрессивной полихимиотерапии. Несомненный интерес и клиническую значимость представляет работа Л. П. Розумбаевой, И. В. Козловой, А. П. Быковой о коморбидности патологии печени, билиарного тракта и псориаза. Полученные авторами результаты необходимо учитывать при оценке эффективности и безопасности базисной терапии дерматоза. Ассоциация двух функциональных заболеваний — синдром раздраженного кишечника и функциональная диспепсия с анализом механизмов развития такой коморбидности с позиций нарушений нейрогуморальной регуляции описана в статье М. А. Осадчук, В. О. Бурдиной. Оригинальное исследование А. А. Марковой, Е. И. Кашкиной, Г. Н. Масляковой посвящено иммуногистохимической диагностике нарушений пролиферации кишечного эпителия у пациентов с язвенным колитом в сопоставлении с длительностью заболевания и активностью патологического процесса в кишке. В разделе «Хирургические аспекты гастроэнтерологии» публикуется статья О. И. Кита, Е. М. Франциянц с соавт., посвященная анализу тканевых факторов регуляции неоангиогенеза и фибринолиза при аденокарциноме прямой кишки, имеющих значимую роль в канцерогенезе. В разделе «Экспериментальная гастроэнтерология» — статья Жеребятьева А. С., Камышного А. М. о региональных различиях распределения популяции иммунных клеток в кишечнике, во многом определяющих специфику патологического процесса в эксперименте. В соответствующем разделе номера — две актуальные лекции, посвященные эозинофильному эзофагиту. В последнее десятилетие число публикаций по этой проблеме в зарубежной литературе возросло почти в 200 раз. Объединенными усилиями гастроэнтерологов, аллергологов и патоморфологов созданы международные согласительные и национальные документы, в которых рассмотрены современные клинико-диагностические критерии эозинофильного эзофагита. У российских пациентов разного возраста эозинофильный эзофагит диагностируют редко. Вниманию читателей представлены две взаимно дополняющие лекции «Особенности диагностики эозинофильного эзофагита» (авторы И. С. Садиков, Д. Ш. Мачарадзе, С. Г. Хомерики) и «Эозинофильный эзофагит у взрослых: особенности диетотерапии» (авторы И. В. Козлова, А. Л. Пахомова). Указанные публикации восполняют дефицит сведений по клиническим особенностям, методам диагностики и немедикаментозного лечения этой патологии. Всегда интересна и полезна врачам рубрика журнала «Случаи из практики». В этом номере представлены два клинических наблюдения. Материал Бабаевой А. И. с соавт. посвящен гемангиомам печени у ревматологических пациентов. Обобщая накопленный опыт, авторы трактуют выявленные при УЗИ гемангиомы печени у пациентов с ревматоидным артритом как системное проявление заболевания, отмечая при этом, что при остеоартрозе гемангиомы печени встречаются достоверно реже. В статье А. Ю. Рябовой с соавт. представлен случай острого холецистита под маской острого инфаркта миокарда. Данное клиническое наблюдение еще раз напоминает практикующим врачам, что холецисто-кардиальный синдром, впервые описанный С. П. Боткиным, часто встречается, но не всегда своевременно распознается у полиморбидных пациентов. В разделе «Материалы конференции» опубликованы материалы выездного пленума НОГР «Болезни органов пищеварения в 21 веке: мультидисциплинарный подход. Гастроэнтерология в возрастном аспекте». Пленум организован совместными усилиями научного общества гастроэнтерологов России и Саратовским государственным медицинским университетом им. В. И. Разумовского МЗ РФ. Саратовский государственный медицинский университет им. В. И. Разумовского — один из старейших медицинских вузов нашей страны. Он был основан более 100 лет назад — в 1909 году. За это время СГМУ преодолел огромный путь от единственного в составе университета факультета до солидного учебного заведения со сложившимися традициями, уникальным медицинским потенциалом и накопленным научным опытом. В университете на протяжении многих лет развивается, обогащаясь новыми идеями и результатами клинических наблюдений, научная гастроэнтерологическая школа, которую основали и продолжают развивать известные хирурги, терапевты, педиатры. В разделе история медицины — яркая и интересная статья об образцовой системе здравоохранения, созданной первым наркомом здравоохранения СССР Николаем Александровичем Семашко. В феврале 2015 года исполняется 80 лет со дня рождения профессора кафедры факультетской терапии Тверской государственной медицинской академии, видного ученого, заслуженного врача России, доктора медицинских наук, профессора Вячеслава Васильевича Чернина. От всего сердца Научное общество гастроэнтерологов России, редакция журнала и коллеги поздравляют Вячеслава Васильевича со славным юбилеем, желают здоровья, радости, интересной и плодотворной работы, творческих побед!
    Ответственный за выпуск редактор,

      заведующая кафедрой терапии педиатрического
    и стоматологического факультетов
    ГБОУ ВПО «Саратовский государственный медицинский
    университет им. В. И. Разумовского» МЗ РФ
    доктор медицинских наук, профессор 
      И. В. Козлова
       

    1. PG «GEOTAR-Media» (Moscow, Russian Federation)
    2. Graduate School of organization and management healthcare (Moscow, Russian Federation)

    Keywords:accreditation of specialists,additional professional education,professional development of specialists,professional standards,continuing medical education

    Abstract:The authors provide information about the factors affecting the quality of medical care, recent changes in the regulatory framework in medical education and its development in Russia compared with developed countries. For healthcare leaders are described the risks for the implementation of these changes in public health practice, are given recommendations for leveling the risks and further improve the quality of medical care in the Russian Federation.

      1. A New, Evidence-based Estimate of Patient Harms Associated with Hospital Care / Ed. by John T. James // Journal of Patient Safety. USA, 2013. Vol. 9, N 3. P. 122 - 128.
      2. John Norcini, FAIMER (Foundation for Advancement of International Medical Education and Research).
     


    Full text is published :
    Balkizov Z.Z., Palevskaya S.A. NEW IN THE DEVELOPMENT OF MEDICAL EDUCATION IN RUSSIA: CONTINUITY AND SPECIALISTS’S ACCREDITATION. Experimental and Clinical Gastroenterology Journal. 2016;129(05):03-11
    Read & Download full text

    1. Public budgetary educational institution of higher education «Tver State Medical University» of the Ministry of Healthcare of the Russia (Tver, Russian Federation)

    Keywords:diet,acid-alkaline balance,oral cavity,caries of teeth,parodontitis

    Abstract:The aim was to investigate the acid-base balance in the mouth and assess the risk of dental disease in practically healthy persons depending on the habitual diet. Materials and methods: The study involved 162 people, divided into three groups: with a mixed diet, with protein foods of animal origin and vegetarians. There were studied the pH value of oral fluid, dental, lingual plaque at stimulation with sucrose and urea. Results: In individuals, characterized by the habitual diet, there are statistically significant persistent changes in acid-base balance in the mouth, which provoke an increased risk of developing dental diseases. At normal mixed diet there is moving the acid-base balance towards weak acidosis that in the presence of other predisposing factors can lead to the risk of development of dental caries. There is a displacement of acid-base balance in the oral cavity to the alkaline side in case the long predominant consumption of protein foods of animal origin, that is dangerous in terms of formation of hard dental deposits and consequently of the development of inflammatory periodontal diseases. In vegetarians, there is a persistent shift of acid-alkaline balance in the mouth in the direction of acidosis, which is a risk factor for development of dental caries.

      1. Румянцев В. А. Кривые рН после стимуляции протеолитической микрофлоры полости рта мочевиной (карбамидом). Новое в стоматологии. - 1998. - № 2. - С. 29 - 34.
      2. Румянцев В. А., Есаян Л. К., Зюзькова Е. Д., Леонова С. О., Наместникова И. В. Нарушения кислотно-основного равновесия в полости рта при общесоматической патологии. Стоматология. - 2013. - № 2. - С. 22 - 26.
      3. Hall-Scullin E., Goldthorpe J., Milsom K., Tickle M. A qualitative study of the views of adolescents on their caries risk and prevention behaviours. BMC Oral Health. - 2015. - Vol. 10, № 15. - Р. 141 - 142.
      4. Kipiani N. V., Iverieli M., Mosemgvdlishvili N., Kipiani N. V., Jafaridze S. Parodontitis pathogenetic factors, their interaction and effects. Georgian Med News. - 2014. -№ 228. - Р. 88 - 91.
     


    Full text is published :
    Namestnikova I.I., Rumyantsev V.A., Egorova E.N. INFLUENCE OF NUTRITION NATURE ON ACID-BASE BALANCE IN THE MOUTH AND THE RISK OF DENTAL DISEASES. Experimental and Clinical Gastroenterology Journal. 2016;129(05):12-15
    Read & Download full text

    1. Rostov Research Institute of Oncology (Rostov-on-don, Russian Federation)

    Keywords:squamous cell carcinoma of the esophagus,uPA,tPA,PAI-1,gender differences

    Abstract:Aim: comparative analysis of uPA-Ag, uPA-act, tPA-Ag, tPA-act, PAI-1-Ag and PAI-1-act in tissues of esophageal squamous cell carcinoma (ESCC) in men (M) and women (W) to clarify some pathogenesis issues. Material and methods. Tumor tissue of ESCC and its perifocal area (19 M and 8 menopausal W aged 38 - 72 years, st II, G2, T2-3N0-1M0-1) were studied by ELISA using standard test kits. Results. ESCC tissue of M showed an increase in both uPA types from the resection line (RL), while in W only uPA-act was increased. tPA-Ag was decreased in tumors of W, tPA-act - in tumors of all patients. Levels of both PAI-1 types were higher in ESCC of M than in W. In M, tPA-Ag in perifocal area was lower than in RL, while in W, on the contrary, it was higher. tPA-Ag/tPA-act coefficient in M tumors was 5.7 times higher than in W; in perifocal area it was reduced in all patients, being at the same time in M lower than in W. Both PAI-1 types were increased in malignant tissues of all patients, prevailing in M tumors, and PAI-1-Ag in peritumoral tissue was higher in M than in W. Conclusions. Significant gender differences were found in expression of uPA, tPA and PAI-1 in tissues of esophageal squamous cell carcinoma. Presence of tumor-associated uPA, PAI-1 and tPA in men and uPA and PAI-1 in women is possible in tumor tissue of esophageal squamous cell carcinoma and its perifocal area. Determination of plasminogen regulation system in tissues of esophageal squamous cell carcinoma can be used for the selection and individualization of postoperative treatments.

      1. Tihan T., Harmon J. W., Wan X. et al. Evidence of androgen receptor expression in squamous and adenocarcinoma of the esophagus. Anticancer Res. 2001; 21: 3107 - 3114.
      2. Sukocheva O. A., Li B., Due S. L. et al. Androgens and esophageal cancer: What do we know? World. J. Gastroenterol. 2015; 21 (20): 6146 - 6156.
      3. Duffy M. J., McGowan P. M., Harbeck N. et al. uPA and PAI-1 as biomarkers in breast cancer: validated for clinical use in level-of-evidence-1 studies. Breast Cancer Res. 2014; 16 (4): 428.
      4. Asuthkar S., Stepanova V., Lebedeva T. et al. Multifunctional roles of urokinase plasminogen activator (uPA) in cancer stemness and chemoresistance of pancreatic cancer. Mol. Biol. Cell. 2013; 24 (17): 2620 - 2632.
      5. Wang JG, Geddings JE, Aleman MM. et al. Tumor-derived tissue factor activates coagulation and enhances thrombosis in a mouse xenograft model of human pancreatic cancer. Blood. 2012; 119 (23): 5543 - 5552.
      6. Geddings J. E., Hisada Y., Boulaftali Y. et al. Tissue factor-positive tumor microvesicles activate platelets and enhance thrombosis in mice. J. Thromb. Haemost. 2016; 14 (1): 153 - 166.
      7. Aĭsina R. B., Mukhametova L. I. [Structure and functions of plasminogen/plasmin system]. Bioorg. Khim. 2014; 40 (6): 642 - 657. Review. Russian.
      8. Huang C., Xie D., Cui J. et al. FOXM1c promotes pancreatic cancer epithelial-to-mesenchymal transition and metastasis via upregulation of expression of the urokinase plasminogen activator system. Clin. Cancer Res. 2014; 20 (6): 1477 - 1488.
      9. Witzel I., Milde-Langosch K., Schmidt M. et al. Role of urokinase plasminogen activator and plasminogen activator inhibitor mRNA expression as prognostic factors in molecular subtypes of breast cancer. Onco. Targets Ther. 2014; 28 (7): 2205 - 2213.
      10. Del Rosso M., Margheri F., Serratì S. et al. The urokinase receptor system, a key regulator at the intersection between inflammation, immunity, and coagulation. Current Pharmaceutical Design. 2011; 17 (19): 1924 - 1943.
      11. Schuliga M. The inflammatory actions of coagulant and fibrinolytic proteases in disease. Mediators Inflamm. 2015; 2015: 4376 - 4395.
      12. Schardt F. W., Schmausser B., Bachmann E. Monoclonal antibodies for immunodetection of fibrin deposits on cancer cells. Histology and Histopathology. 2013; 28 (8): 993 - 998.
      13. Yang D., Kuan C. Y. Anti-tissue Plasminogen Activator (tPA) as an effective therapy of neonatal hypoxia-ischemia with and without inflammation. CNS Neuroscience & Therapeutics. 2014.
      14. Франциянц Е. М., Комарова Е. Ф., Верескунова М. И., Черярина Н. Д. Состояние тканевой фибринолитической системы при опухолях органов женской репродуктивной системы. Успехи современного естествознания. 2014; (4): 46 - 48.
      15. Xiao W., Hsu Y.-P., Ishizaka A. et al. Sputum cathelicidin, urokinase plasminogen activation system components, and cytokines discriminate cystic fibrosis, COPD, and asthma inflammation. Chest. 2005; 128 (4): 2316 - 2326.
      16. Ma Z., Paek D., Oh C. K. Plasminogen activator inhibitor-1 and asthma: role in the pathogenesis and molecular regulation. Clinical and Experimental Allergy. 2009; 39 (8): 1136 - 1144.
      17. Iwaki T., Urano T., Umemura K. PAI-1, progress in understanding the clinical problem and its aetiology. British Journal of Haematology. 2012; 157 (3): 291 - 298.
      18. Yang L. F., Ji X. G., Xing M. D. et al. The relationship between esophageal cancer and androgen-estrogen receptors. Zhongguo Xiongxinxieguan Waike Linchuang Zazhi. 2001; 8: 154 - 156.
      19. Flüchter S. H., Weiser R., Gamper C. The role of hormonal treatment in prostate cancer. Recent Results Cancer Res. 2007; 175: 211 - 237.
      20. Levin E. R., Pietras R. J. Estrogen receptors outside the nucleus in breast cancer. Breast Cancer Res Treat. 2008; 108: 351 - 361.
      21. Cook M. B., Wood S. N., Cash B. D. et al. Association between circulating levels of sex steroid hormones and Barrett’s esophagus in men: a case-control analysis. Clin. Gastroenterol. Hepatol. 2015; 13: 673 - 682.
      22. Cooper S. C., Trudgill N. J. Subjects with prostate cancer are less likely to develop esophageal cancer: analysis of SEER 9 registries database. Cancer Causes Control. 2012; 23: 819 - 825.
      23. Tang L., Han X. The urokinase plasminogen activator system in breast cancer invasion and metastasis. Biomedicine and Pharmacotherapy. 2013; 67 (2): 179 - 182.
      24. Chen H., Peng H., Liu W. et al. Silencing of plasminogen activator inhibitor-1 suppresses colorectal cancer progression and liver metastasis. Surgery. 2015; 158 (6): 1704 - 1713.
      25. Schuliga M., Langenbach S., Xia Y. C., et al. Plasminogen-stimulated inflammatory cytokine production by airway smooth muscle cells is regulated by annexin A2. The American Journal of Respiratory Cell and Molecular Biology. 2013; 49 (5): 751 - 758.
      26. Kwaan H. C., McMahon B. The role of plasminogen-plasmin system in cancer. Cancer Treatment and Research. 2009; 148: 43 - 66.
      27. Shimomura M., Hinoi T., Ikeda S. et al. Preservation of peritoneal fibrinolysis owing to decreased transcription of plasminogen activator inhibitor-1 in peritoneal mesothelial cells suppresses postoperative adhesion formation in laparoscopic surgery. Surgery. 2013; 153 (3): 344 - 356.
      28. Stewart A. G., Xia Y. C., Harris T. et al. Plasminogen-stimulated airway smooth muscle cell proliferation is mediated by urokinase and annexin A2, involving plasmin-activated cell signalling. British Journal of Pharmacology. 2013; 170 (7): 1421 - 1435.
     


    Full text is published :
    Kit O.I., Frantsiyants E.M., Kozlova L.S., Kolesnikov E.N. et al. GENDER DIFFERENCES IN TISSUE CASCADE OF ACTIVATION OF PLASMINOGEN AND PAI-1 IN ESOPHAGEAL SQUAMOUS CELL CARCINOMA. Experimental and Clinical Gastroenterology Journal. 2016;129(05):16-21
    Read & Download full text

    1. Medical University of South Ural State Medical University (Chelyabinsk, Russian Federation)
    2. Belarusian State Medical University (Minsk, Belarus)

    Keywords:Helicobacter pylori,chronic pancreatitis,eradication therapy

    Abstract:Relevance. Currently, there is a need to study the genetic diversity of H.pylori in patients with variety of acid-related diseases to develop new strategies for the treatment of patients with H.pylori to predict high efficiency of treatment. Objective: To assess the effectiveness of schemes of eradication therapy in patients with chronic pancreatitis and concomitant H.pylori infection. Materials and methods. The study included 108 patients with H.pylori infection: 63 patients had chronic pancreatitis and were concomitant with H.pylori-infection and 45 patients were without chronic pancreatitis and had H.pylori infection with a chronic gastritis. All patients were determined by factors of pathogenicity of H.pylori by immunoblotting. After forming the group randomized patients received eradication therapy scheme I and the scheme I with inclusion of bismuth tripotassium dicitrate. Conclusions. The effectiveness of H.pylori eradication therapy is dependent on the genetic component of H.pylori. In the presence of H.pylori pathogenicity factors p33, p30, p26, p19, p17 in order to increase the effectiveness of treatment the scheme of eradication therapy I line drugs bismuth tri dicitrate should be included.

      1. Пасечников В. Д., Чуков С. З. Значение геномной гетерогенности штаммов НР в развитии ассоциированной патологии гастродуоденальной зоны. Рос. журнал гастроэнтерологии, гепатологии, колопроктологии. 2000; 3: 7 - 11.
      2. Аруин Л. И. Helicobacterpyloriв патогенезе язвенной болезни: что известно и что узнать предстоит. // 5_я сессия Российской группы по изучению НР. - Омск, 1997 - С. 3 - 5.
      3. Ивашкин В. Т., Лапина Т. Л. Роль молекул адгезии в патогенезе инфекции Helicobacterpylori. Рос. журнал гастроэн. гепатол. колопокт. 1997; 6: 32 - 37.
      4. Аруин Л. И., Капуллер Л. Л., Исаков В. А. Морфологическая диагностика болезней желудка и кишечника. - М.: Триада_Х, 1998. - 496 с.
      5. Van Doorn L. J. Geographic distribution of vacA allelic types of Helicobacter pylori. Gastroenterology. 1999; 116: 823 - 830.
      6. Щукин. И. Инфекция Helicobacter pylori / Н. И. Ющук, В. Т. Ивашкин, И. В. Маев // Мед. Газета, 2006. - № 40.
      7. Фадеенко Г. Д. Инфекция Helicobacterpylori: итоги 20-летнего изучения ее патогенности // Вестник Харьковского нац. универс., 2004. - № 614.
      8. De Francesco V., Ierardi E, Hassan C., Zullo A. Helicobacter pylori therapy: Present and future // World J. GastrointestPharmacol. Ther. 2012. № 3 (4). Р. 68 - 73.
      9. Castro-Fernandez M., Vargas-Romero J. Infection with Helicobacter pylori. Prevalence, research and impact of antibiotic resistance // Rev. Esp. Enferm. Dig. 2009. № 101 (11). Р. 743 - 756.
      10. Wu W., Yang Y, Sun G Recent Insights into Antibiotic Resistance in Helicobacter pylori Eradication // Gastroenterol. Res. Pract. 2012. 2012. 723183.
      11. Francesco V. D., Zullo A, Hassan C., et al. Mechanisms of Helicobacter pylori antibiotic resistance: An updated appraisal // World J. Gastrointest. Pathophysiol. 2011. № 2 (3). Р. 35 - 41.
      12. Маев И. В., Казюлин А. Н., Кучерявый Ю. А. Хронический панкреатит. - М.: ОАО «Издательство «Медицина», 2005.
     


    Full text is published :
    Sarsenbaeva A.S., Domracheva E.V., Rustamov M.N. CLINICAL RELEVANCE HELICOBACTER PYLORI GENOTYPES IN PATIENTS WITH CHRONIC PANCREATITIS AND CONCOMITANT INFECTIONS HELICOBACTER PYLORI. Experimental and Clinical Gastroenterology Journal. 2016;129(05):22-27
    Read & Download full text

    1. Federal State Scientific Institution Irkutsk Scientific Center of Surgery and Traumatology (Irkutsk, Russian Federation)

    Keywords:ulcerative colitis,descending colon of rats,technology of the surgery

    Abstract:Background: Ulcerative colitis (UC) is a chronic immune inflammatory condition of the colon with an unknown aetiology, leading to disability and reduced quality of life of patients. UC primarily affects young adults. In most cases, inflammatory bowel disease (IBD) debuts at reproductive age. The incidence of UC and severe clinical course has increased overall across the world. The study of the mechanisms of pathogenesis and aetiology of this disease contributes to the development of new effective methods of treatment. Objective: The aim of our study was to develop technology of the surgery directed to induction of reversible ischemic damage, the erosive-ulceration of gut mucosae (descending colon) at rats of the WISTAR line. Materials and methods: Experimental research was done using male rats «Wistar» (n=40), their age was more than 6 months, weight of body is 280 - 350 grams. The animals were separated into 3 groups: 1 - (n=14) Sholimov’s operative method, 2 group (n=16) - model using special technology, 3 group (n=10) - Coopr’s H. S. induction ulcerative colitis. Observation was been done during 10 days. We offered special surgical technique: parietal ligation on every vasa recta of colon descendens of rats the length 3 cm along colon, on the apex vesicae and then vasa recta are cut. Then during 7 days 1% solution of dextran sulfate sodium (DSN) was given for experimental animals after postoperative period. By the histological biopsy of colon mucosa the results were estimated. Results/Conclusion: we have created erosive-ulceration of gut mucosae (descending colon) of rat with productive inflammation, vasculitis and plasmatic impregnation of the vessel walls and intimal thickening. Our model of ulcerative colitis can be used for the development and testing of new methods for the study and treatment of this pathology.

      1. Second European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis, A. Dignass et all // Journal of Crohn’s and Colitis. - 2012. - V. 6 (10). - December 2012. - P. 965 - 990
      2. William A Rose, Kaori Sakamoto, Cynthia A Leifer: Multifunctional role of dextran sulfate sodium for in vivo modeling of intestinal diseases, BMC Immunology 2012, 13:41 doi: 10.1186/1471-2172-13-41
      3. Martina Perse and Anton Cerar: Dextran Sodium Sulphate Colitis Mouse Model: Traps and Trics. J. of Biomedical and Biotechnology, volume 2012, article ID 718617, 13 pages.
      4. Лепехова С. А. Программа стандартных операционных процедур: лабораторные животные (прием, содержание, уход и контроль здоровья животных в вивариях медицинского учреждения): учеб. пособие. Иркутск: НЦРВХ СО РАМН; ИГМУ, 2012; 96 с.].
      5. Шалимов С. А., Радзиховский А. П., Кейсевич Л. В. Руководство по экспериментальной хирургии. - М., 1989. - с. 207
      6. Puneet Kaur Randhawa, Kavinder Singh, Nirmal Singh, and Amteshwar Singh Jaggi. A Review on Chemical-Induced Inflammatory Bowel Disease Models in Rodents. Korean J. Physiol. Pharmacol. Vol. 18: 279-288, August, 2014
      7. W. Elsheikh, K. L. Flannigan, W. Mcknight, J. G. P. Ferraz, J. L. Wallace. Dextran sulfate sodium induces pan-gastroenteritis in rodents: implicationsfor studies of colitis. Journal of physiology and pharmacology 2012, 63, 5, 463 - 469
      8. H. S. Cooper, S. N. Murthy, R. S. Shah, and D. J. Sedergran, «Clinicopathologic study of dextran sulfate sodium experimental murine colitis,» Laboratory Investigation, vol. 69, no. 2, pp. 238 - 249, 1993.
     


    Full text is published :
    Kim A.D., Lepekhova S.A., Chashkova Ye.Yu., Gol’dberg O.A., Shedoeva L.R. TECHNOLOGY SURGICAL INTERVENTION IN ULCERATIVE COLITIS MODELING DESCENDING PART OF THE COLON IN RATS LINE «WISTAR». Experimental and Clinical Gastroenterology Journal. 2016;129(05):28-32
    Read & Download full text

    1. State budget institution of higher professional education «Samara State Medical University» Ministry of Health of the Russian Federation (Samara, Russian Federation)

    Keywords:consensus of the Working Group III,diagnosis and treatment of H.pylori-infection,cancer prevention

    Abstract:The purpose of the review. Outline the main points of consensus III Working Group Italian for the diagnosis and treatment of H.pylori-infection. The work of the Working Group III was the clarification of certain provisions of the Maastricht IV consensus, and, namely, the nature of H.pylori relationship with gastroesophageal reflux disease, functional dyspepsia, NSAID / aspirin gastropathy, extra-gastric diseases, detailed scope of the invasive and non-invasive methods of investigation, treatment algorithms updated H.pylori-infection antibiotic growth conditions. Indented understanding of the role of H.pylori eradication in the prevention of gastric cancer.

      1. Zagari R. M., Romano M., Ojetti V., et al. Guidelines for the management of Helicobacter pylori infection in Italy: The III Working Group Consensus Report 2015 // Digestive and Liver Disease. - 2015. - Vol. 47. - Р. 903 - 912.
      2. Malfertheiner P., Megraud F., O’Morain C. A., et al. Management of Helicobacter pylori infection - the Maastricht IV/Florence Consensus Report // Gut. - 2012. - Vol. 61. - Р. 646 - 64.
      3. Gisbert J. P., Calvet X. Helicobacter pylori test and treat strategy for managementof dyspepsia: a comprehensive review // Clinical and Translational Gastroenterology. - 2013. - Vol. 28. - e32.
      4. Eusebi L. H., Zagari R. M., Bazzoli F. Epidemiology of Helicobacter pylori infection // Helicobacter. - 2014. - Vol. 19 (Suppl. 1). - Р. 1 - 5.
      5. Zagari R. M., Law G. R., Fuccio L., et al. Epidemiology of functional dyspepsia andsubgroups in the Italian general population: an endoscopic study //Gastroenterology. - 2010. - Vol. 138. - Р. 1302 - 11.
      6. Mana F., Vandebosch S., Miendje Deyi V., et al. Prevalence of and risk factors for H.pylori infection in healthy children and young adults in Belgium anno 2010/2011 // Acta Gastroenterol Belg. - 2013. - Vol. 76. - Р. 381 - 5.
      7. Rossi S., Crocetti E., Capocaccia R., et al. Estimated of cancer burden in Italy //Tumori. - 2013. - Vol. 99. - Р. 416 - 24.
      8. Zagari R. M., Fuccio L., Bazzoli F. Investigating dyspepsia // BMJ 2008. - 337a: 1400.
      9. Moayyedi P. Helicobacter pylori eradication for functional dyspepsia: whatare we treating?: Comment on «Helicobacter pylori eradication in functionaldyspepsia» // Archives of Internal Medicine. - 2011. - Vol. 171. - Р. 1936 - 7.
      10. Ronkainen J, Agréus L. Epidemiology of reflux symptoms and GORD // Best Practice & Research Clinical Gastroenterology. - 2013. - Vol. 27. - Р. 325 - 37.
      11. Lee Y. C., Chen T. H., Chiu H. M., et al. The benefit of mass eradication of Helicobacter pylori infection: a community-based study of gastric cancer prevention // Gut. - 2013. - Vol. 62. - Р. 676 - 82.
      12. Yaghoobi M., Farrokyar F., Yuan Y., et al. Is there an increased risk of GERD after Helicobacter pylori eradication? A meta-analysis //American Journal of Gastroenterology. - 2010. - Vol. 105. - Р. 1007 - 13.
      13. Qian B., Shijie M., Shang L., et al. Effect of HP eradication on gastroesophageal reflux disease //Helicobacter. - 2011. - Vol. 16. - Р. 255 - 65.
      14. Fox J. G., Kuipers E. J. Long-term proton pump inhibitor administration, HP and gastric cancer: lessons from the gerbil // Gut. - 2011. - Vol. 60. - Р. 567 - 8.
      15. Abraham N. S., Hlatky M. A., Antman E. M., et al. Expert Consensus Documenton the concomitant use of proton pump inhibitors and thienopyridines: afocused update of the ACCF/ACG/AHA 2008 expert consensus document onreducing the gastrointestinal risks of antiplatelet therapy and NSAID use: areport of the American College of Cardiology Foundation Task Force on ExpertConsensus Documents // Circulation. - 2010. - Vol. 122. - Р. 2619 - 33.
      16. Levi M. M., Eerenberg E., Löwenberg E., et al. Bleeding in patients using new anti-coagulants or antiplatelet agents: risk factors and management //Netherlands Journal of Medicine. - 2010. - Vol. 68. - Р. 68 - 76.
      17. Qu X. H., Huang X. L., Xiong P., et al. Does Helicobacter pylori infection play a role iniron deficiency anemia? A meta-analysis // World Journal of Gastroenterology. - 2010. - Vol. 16. - Р. 886 - 96.
      18. Goddard A. F., James M. W., McIntyre A. S., et al. Guidelines for the management of iron deficiency anaemia // Gut. - 2011. - Vol. 60. - Р. 1309 - 16.
      19. Huang X., Qu X., Yan W., et al. Iron deficiency anaemia can be improved after eradication of Helicobacter pylori // Postgraduate Medical Journal. - 2010. - Vol. 86. - Р. 272 - 8.
      20. Yuan W., Li Yumin, Yang Kehu, et al. Iron deficiency anemia in Helicobacter pylori infection: meta-analysis of randomized controlled trials //Scandinavian Journal of Gastroenterology. - 2010. - Vol. 45. - Р. 665 - 76.
      21. Annibale B., Capurso G., Lahner E., et al. Concomitant alterations in intra-gastric pH and ascorbic acid concentration in patients with Helicobacter pylori gastritis and associated iron deficiency anaemia // Gut. - 2003. - Vol. 52. - Р. 496 - 501.
      22. Franchini M., Cruciani M., Mengoli C., et al. Effect of Helicobacter pylorieradication on platelet count in idiopathic thrombocytopenic purpura: a sys-tematic review and meta-analysis //Journal of Antimicrobial Chemotherapy. -2007. - Vol. 60. - Р. 237 - 46.
      23. Stasi R., Sarpatwari A., Segal J. B., et al. Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review // Blood. - 2009. - Vol. 113. - Р. 1231 - 40.
      24. Arnold D. M., Bernotas A., Nazi I., et al. Platelet count response to HP treatment in patients with immune thrombocytopenic purpura with and without HP infection: a systematic review //Haematologica. - 2009. - Vol. 94. - Р. 850 - 6.
      25. Lahner E., Persechino S., Annibale B., et al. (Other than iron) and Helicobacter pylori infection: a systematic review // Helicobacter. - 2012. - Vol. 17. - Р. 1 - 15.
      26. Wang Z. W., Yan L., Huang L. Y., et al. Helicobacter pylori infection contributesto high risk of ischemic stroke: evidence from a meta-analysis // Journal of Neurology. - 2012. - Vol. 259. - Р. 2527 - 33.
      27. Gravina A. G., Federico A., Ruocco E., et al. Helicobacter pylori infection but notsmall intestinal bacterial overgrowth may play a pathogenic role in rosacea //United European Gastroenterology Journal. - 2015. - Vol. 3. - Р. 17 - 24.
      28. Ferwana M, Abdulmajeed I, Alhajiahmed A, et al. Accuracy of urea breath testin Helicobacter pylori infection: meta-analysis // World Journal of Gastroenterology. - 2015. - Vol. 2. - Vol. 1305 - 14.
      29. Gisbert J. P., De La M. F., Abraira V. Accuracy of monoclonal stool antigen test for the diagnosis of infection: a systematic review and meta-analysis //American Journal of Gastroenterology. - 2006. - Vol. 101. - Р. 1921 - 30.
      30. Calvet X., Lario S., Ramirez-Lazaro M. J., et al. Accuracy of monoclonal stool tests for determining cure of Helicobacter pylori infection after treatment //Helicobacter. - 2010. - Vol. 15 (3). - Р. 201 - 05.
      31. Vaira D., Gatta L., Ricci C., et al. Helicobacter pylori: diseases, tests and treatment //Digestive and Liver Disease. - 2001. - Vol. 33. - Р. 788 - 94.
      32. Sanchez-Delgado J., Genè E., Suarez D., et al. Has HP prevalence in bleeding peptic ulcer been underestimated? A meta-regression //American Journal of Gastroenterology. - 2011. - Vol. 106. - Р. 398 - 405.
      33. Ekstrom A. M., Held M., Hansonn L. E., et al. Helicobacter pylori in gastriccancer established by CagA immunoblot as a marker of past infection //Gastroenterology. - 2001. - Vol. 121. - Р. 784 - 91.
      34. De Francesco V., Zullo A., Ierardi E., et al. Phenotypic and genotypic Helicobacterpylori clarithromycin resistance and therapeutic outcome: benefits and limits //Journal of Antimicrobial Chemotherapy. - 2010. - Vol. 65. - Р. 327 - 32.
      35. Rimbara E., Noguchi N., Kawai T., et al. Fluoroquinolone resistance in Helicobacter pylori: role of mutations at position 87 and 91 of GyrA on the levelof resistance and identification of a resistance conferring mutation in GyrB //Helicobacter. - 2012. - Vol. 17. - Р. 36 - 42.
      36. Cambau E., Allerheiligen V., Coulon C., et al. Evaluation of a new test, genotype HelicoDR, for molecular detection of antibiotic resistance in Helicobacterpylori // Journal of Clinical Microbiology. - 2009. - Vol. 47. - Р. 3600 - 7.
      37. De Francesco V., Zullo A., Giorgio F., et al. Change of point mutations in the H.pylori rRNA associated with clarithromycin resistance in Italy // Journal of Medical Microbiology. - 2014. - Vol. 63. - Р. 453 - 7.
      38. Liu Q., Qi D., Kang J., et al. Efficacy of real-time PCR-based detection of Helicobacter pylori infection and genotypic resistance-guided quadruple therapy as the first-line treatment for functional dyspepsia with Helicobacter pylori infection //European Journal of Gastroenterology and Hepatology. - 2015. - Vol. 27. - Р. 221 - 5.
      39. Figura N., Crabtree J. E., Dattilo M. In-vitro activity of lansoprazole against Helicobacter pylori //Journal of Antimicrobial Chemotherapy. - 1997. - Vol. 39. - Р. 585 - 90.
      40. Villoria A., Garcia P., Calvet X., et al. Meta-analysis: high-dose proton pump inhibitors vs. standard dose in triple therapy for Helicobacter pylori eradication //Alimentary Pharmacology and Therapeutics. - 2008. - Vol. 28. - Р. 868 - 77.
      41. Farup P. G., Lange O. J., Tholfsen J., et al. The effect of Helicobacter pylori retreatment with ranitidine bismuth citrate, clarithromycin, and metronidazole depends on the first-line therapy //Journal of Clinical Gastroenterology 2002. - Vol. 35. - Р. 379 - 82.
      42. Almeida N., Romãozinho J. M., Donato M. M., et al. Triple therapy with high-dose proton-pump inhibitor, amoxicillin, and doxycycline is useless for Helicobacter pylori eradication: a proof-of-concept study //Helicobacter 2014. - Vol. 19. - Р. 90 - 7.
      43. Megraud F., Coenen S., Versporten A., et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption // Gut. - 2013. - Vol. 62. - Vol. 34 - 42.
      44. Yang Y., Ford A. C., Khan K. J., et al. Optimum duration of regimens for Helicobacter pylori eradication. Cochrane Database of Systematic Reviews 2013. Art No: CD370083.
      45. Zullo A., Esposito G., Ridola L., et al. Prevalence of lesions detected atupper endoscopy: an Italian survey //European Journal of Internal Medicine. - 2014. - Vol. 25. - Р. 772 - 6.
      46. Zullo A., Esposito G., Ridola L., et al. Prevalence of lesions detected atupper endoscopy: an Italian survey //European Journal of Internal Medicine. - 2014. - Vol. 25. - Р. 772 - 6.
      47. Gatta L., Vakil N., Vaira D., et al. Global eradication rates for Helicobacter pylori infection: systematic review and meta-analysis of sequential therapy // BMJ. - 2013. - Vol. 347. - f4587.
      48. Molina-Infante J., Romano M., Fernandez-Bermejo M., et al. Optimized non-bismuth quadruple therapies cure most patients with Helicobacter pylori infection in populations with high rates of antibiotic resistance // Gastroenterology. - 2013. - Vol. 145. - Р. 121 - 8.
      49. Malfertheiner P., Bazzoli F., Delchier J., et al. Helicobacter pylori eradication witha capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: arandomised, open-label, non-inferiority, phase 3 trial, Pylera Study Group //Lancet. - 2011. - Vol. 377. - Р. 905 - 13.
      50. Liou J. M., Lin J., Chang C. Y., et al. Levofloxacin-based and clarithromycin-basedtriple therapies as first-line and second-line treatments for Helicobacter pylori infection: a randomised comparative trial with cross-over design // Gut. - 2010. - Vol. 59. - Р. 572 - 8.
      51. Federico A., Gravina A. G., Miranda A., et al. Eradication of Helicobacter pylori infection: which regimen first? //World Journal of Gastroenterology. - 2014. - Vol. 20. - 665 - 72.
      52. Federico A., Nardone G., Gravina A. G., et al. Efficacy of 5-day levofloxacin-containing concomitant therapy in eradication of Helicobacter pylori infection //Gastroenterology. - 2012. - Vol. 143. - Р. 55 - 61.
      53. Saracino I. M., Zullo A., Holton J., et al. High prevalence of primary antibioticresistance in Helicobacter pylori isolates in Italy // Journal of Gastrointestinal and Liver Diseases. - 2012. - Vol. 21. - Р. 363 - 5.
      54. Chung J. W., Lee J. H., Yung H. Y., et al. Second-line Helicobacter pylori eradication: arandomized comparison of 1 week or 2 week bismuth-containing quadruple therapy // Helicobacter. - 2011. - Vol. 16. - Р. 289 - 94.
      55. Rokkas T., Sechophulos P., Robotis I., et al. Cumulative HP eradication rates in clinical practice by adopting first and second-line regimens proposed by the Maastricht III consensus and a third-line empirical regimen // American Journal of Gastroenterology. - 2009. - Vol. 104. - Р. 21 - 5.
      56. Gisbert J. P., Calvet X. Review article: rifabutin in the treatment of refractory Helicobacter pylori infection //Alimentary Pharmacology and Therapeutics. - 2012. - Vol. 35. - Р. 209 - 21.
      57. Fiorini G., Vakil N., Zullo A., et al. Culture-based selection therapy for patientswho did not respond to previous treatment for Helicobacter pylori infection // Clinical Gastroenterology and Hepatology. - 2013. - Vol. 11. - Р. 507 - 10.
      58. Ruggero P. Use of probiotics in the fight against Helicobacter pylori //World Journal of Gastroenterology. - 2014. - Vol. 5. - Р. 384 - 91.
      59. Szajewska H., Horvath A., Piwowarczyk A. Meta-analysis: the effects of Saccha-romyces boulardii supplementation on Helicobacter pylori eradication ratesandside effects during treatment // Alimentary Pharmacology and Therapeutics. - 2010. - Vol. 32. - Р. 1069 - 79.
      60. Wang Z. H., Gao Q. Y., Fang J. Y. Meta-analysis of the efficacy and safety of Lactobacillus-containing and Bifidobacterium-containing probiotic com-pound preparation in Helicobacter pylori eradication therapy // Journal of Clinical Gastroenterology. - 2013. - Vol. 47. - Р. 25 - 32.
      61. Zheng X., Lyu L., Mei Z. Lactobacillus-containing probiotic supplemen-tation increases Helicobacter pylori eradication rate: evidence from a meta-analysis // Revista Espanola de Enfermedades Digestivas. - 2013. - Vol. 105. - Р. 445 - 53.
      62. Zojaji H., Ghobakhlou M., Rajabalinia H., et al. The efficacy and safety of adding the probiotic Saccharomyces boulardii to standard triple therapy for eradication of HP: a randomized controlled trial // Gastroenterology and Hepatology from Bed to Bench. - 2013. - Vol. 6 (Suppl. 1). - S99-104.
      63. Manfredi M, Bizzarri B, Sacchero RI, et al. Helicobacter pylori infection inclinical practice: probiotics and a combination of probiotics + lactoferrin improve compliance, but not eradication, in sequential therapy //Helicobacter. - 2012. - Vol. 17. - Р. 254 - 63.
      64. Ford A. C., Forman D., Hunt R. H., et al. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials //BMJ. - 2014. - Vol. 348. - g. 3174.
      65. Wang H. L., Zhou P. Y., Liu P., et al. Role of p16 gene promotor methylation in gastric carcinogenesis: a meta-analysis // Molecular Biology Reports. - 2014. - Vol. 41. - Р. 4481 - 92.
      66. Marcos-Pinto R., Dinis-Ribeiro M., Carneiro F., et al. First-degree relatives of early-onset gastric cancer patients show a high risk for gastric cancer: phenotype and genotype profile //Virchows Archiv. - 2013. - Vol. 463. - Р. 391 - 9.
      67. McLean M. H., El-Omar E. M. Genetics of gastric cancer //Nature Reviews Gastroenterology & Hepatology. - 2014. - Vol. 11. - Р. 664 - 74.
      68. Yan S., Li B., Bai Z. Z., et al. Clinical epidemiology of gastric cancer in Hehuang valley of China: a 10-year epidemiological study of gastric cancer //World Journal of Gastroenterology. - 2014. - Vol. 20 (30). - Р. 10486 - 94.
      69. Dorji D., Dendup T., Malaty H. M., et al. JM. Epidemiology of Helicobacter pylori in Bhutan: the role of environment and geographic location // Helicobacter. - 2014. - Vol. 19. - Р. 69 - 73.
      70. Tsukanov V. V., Butorin N. N., Maady A. S., et al. Helicobacter pylori infection, intestinal metaplasia, and gastric cancer risk in Eastern Siberia // Helicobacter. - 2011. - Vol. 16. - Р. 107 - 12.
      71. Rugge M., Correa P., Dixon M. F., et al. Gastric mucosa atrophy: inter-observer consistency using new criteria for classification and grading. Alimentary //Pharmacology and Therapeutics. - 2002. - Vol. 16. - Р. 1249 - 59.
      72. Dinis-Ribeiro M., Areia M., de Vries A. C., et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG). European Society of Pathology, and the Sociedade Portoguesa de Endoscopia Digestiva (SPED) // Endoscopy. - 2012. - Vol. 44. - Р. 74 - 94.
      73. Sanduleanu S., Jonkers D., de Bruine A., et al. Non-Helicobacter pylori bacterial flora during acid-suppressive therapy: differential findings in gastric juice and gastric mucosa // Alimentary Pharmacology and Therapeutics. - 2001. - Vol. 15. - Р. 379 - 88.
      74. Fuccio L., Zagari R. M., Eusebi L. H., et al. Meta-analysis: can Helicobacter pylorieradication treatment reduce the risk for gastric cancer? //Annals of Internal Medicine. - 2009. - Vol. 151. - Р. 121 - 8.
      75. Yamaji Y., Watabe H., Yoshida H., et al. High-risk population for gastric cancer development based on serum pepsinogen status and lifestyle factors //Helicobacter. - 2009. - Vol. 14. - Р. 81 - 96.
      76. Ford A. C., Forman D., Hunt R. H., et al. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials //BMJ. - 2014. - Vol. 348. - g. 3174.
      77. Dinis-Ribeiro M., Yamaki G., Miki K., et al. Meta-analysis on the validity of pepsinogen test for gastric carcinoma, dysplasia or chronic atrophic gastritis screening // Journal of Medical Screening. - 2004. - Vol. 11. - Р. 141 - 7.
      78. Rabitti S., Greenwood D., Eusebi L. H., et al. Sensitivity and specificity of thepanel test «Gastropanel» for the non invasive diagnosis of atrophic gastritis //Digestive and Liver Disease. - 2014. - Vol. 46 (Suppl. 2). - S90.
      79. Sinning C., Schaefer N., Standop J., et al. Gastric stump carcinoma - epidemiology and current concepts in pathogenesis and treatment // European Journal of Surgical Oncology. - 2007. - Vol. 33. - Р. 2022 - 6.
      80. Rokkas T., Sechopoulos P., Pistiolas P., et al. Helicobacter pylori infection and gastric histology in first degree relatives of gastric cancer patients: a meta-analysis //European Journal of Gastroenterology and Hepatology. - 2010. - Vol. 22. - Р. 1128 - 31.
      81. Poulsen A. H., Christensen S., McLaughlin J. K., et al. Proton pump inhibitors and risk of gastric cancer: a population based cohort-study // British Journal of Cancer. - 2009. - Vol. 100. - Р. 1503 - 7.
      82. Santibanez M., Alguacil I., Garcia De La Hera M., et al. Occupational exposures and risk of stomach cancer by histological type // Occupational and Environmental Medicine. - 2012. - Vol. 69. - Р. 268 - 75.
      83. Dinis-Ribeiro M., Areia M., de Vries A. C., et al. Management of precancerous conditions and lesions in the stomach (MAPS): guideline from theEuropean Society of Gastrointestinal Endoscopy (ESGE), European Heli-cobacter Study Group (EHSG). European Society of Pathology, and theSociedade Portoguesa de Endoscopia Digestiva (SPED) // Endoscopy. - 2012. - Vol. 44. - Р. 74 - 94.
      84. Ивашкин В. Т., Шептулин А. А., Лапина Т. Л. и соавт. Рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению функциональной диспепсии //Российский журнал гастроэнтерологии, гепатологии, колопроктологии. - 2012. - № 3. - С. 80 - 92.
     


    Full text is published :
    Osadchuk A.M., Davydkin I.L., Gricenko T.A. OVERVIEW BASIC PROVISIONS CONSENSUS OF THE III WORKING ITALIAN GROUP FOR DIAGNOSIS AND TREATMENT OF H.PYLORI-INFECTION. Experimental and Clinical Gastroenterology Journal. 2016;129(05):33-44
    Read & Download full text

    1. State Organization «Saint-Petersburg I. I. Dzhanelidze Research Institute of Emergency» (St. Petersburg, Russian Federation)
    2. State Organization «Saint-Petersburg I. I. Dzhanelidze Research Institute of Emergency» (St. Petersburg, Russian Federation)
    3. FMBA FGBUN «Institute of Toxicology of the Federal Medical and Biological Agency (St. Petersburg, Russian Federation)

    Keywords:acute poisoning,ethanol,alcoholic fatty liver disease,remaxol

    Abstract:The aim of the study was to increase the efficiency of the treatment of acute ethanol intoxication in patients with alcoholic fatty liver disease. The article presents the results which received during the investigation and treatment of 166 patients with acute ethanol intoxication on the background of alcoholic fatty liver disease Patients were assessed by the severity scale APACHE-II. Were studied the dynamics of clinical, laboratory, biochemical parameters, the state of the antioxidant system activity and lipid peroxidation. The study found the effect of the combination hepatoprotective drug remaxol on the many links of metabolism, which was confirmed by the dynamics of biochemical parameters. There was a quick correction of hyperlactatemia, an effective reduction of ALT activity, the absence of reduction of albumin and urea concentration in the somatic period of ethanol poisoning. Period of using remaxol there was improvement in the clinical course of the disease, which manifested by the reduce the incidence of delirium tremens and shorten the duration of treatment of patients.

      1. Еpмолов А. С., Епифанова Н. М., Pомасенко М. В., Лужников Е. А., Ишмухаметов А. И., Голиков П. П., Хватов В. Б., Кукшина А. А., Давыдов Б. В., Куксова Н. С., Федоpова Н. В., Сыpомятникова Е. Д. Pоль гипеpбаpической оксигенации в лечении постгипоксической энцефалопатии токсического генеза. Анестезиология и реаниматология. 1998; 6: 20 - 25.
      2. Ливанов Г. А., Калмансон М. Л., Батоцыренов Б. В., Глушков С. И., Лодягин А. Н. Фармакологическая коррекция последствий гипоксии у больных в токсической коме вследствие острых отравлений ядами нейротропного действия Анестезиология и реаниматология. 2002; 2: 14 - 17
      3. Ливанов Г. А., Батоцыренов Б. В., Калмансон М. Л., Лодягин А. Н., Васильев С. А. Коррекция критических состояний при острых отравлениях ядами нейротропного действия на раннем госпитальном этапе. Скорая медицинская помощь. 2005; Т. 6 (1): 47 - 52.
      4. Ливанов Г. А., Мороз В. В., Батоцыренов Б. В., Лодягин А. Н., Андрианов А. Ю., Базарова В. Г. Пути фармакологической коррекции последствий гипоксии при критических состояниях у больных с острыми отравлениями. Анестезиология и реаниматология. 2003; 2: 51 - 54.
      5. Лужников Е. А., Леженина Н. Ф., Гольдфарб Ю. С., Епифанова Н. М. Особенности формирования и течения токсико-гипоксической энцефалопатии при острых отравлениях веществами нейротоксического действия. Анестезиология и реаниматология. 2005; 6: 4 - 8.
      6. Лужников Е. А., Костомарова Л. Г. Острые отравления: Руководство для врачей. 2-е изд., М.: Медицина, 2000.
      7. Рябов Г. А. Гипоксия критических состояний. М. 1988.
      8. De Pualo J. R., Folstein V. F., Gordon D. Psychiatric screening on a neurological ward. Psychological Medicane. 1980; 10: 125 - 132.
      9. Granger C. Kelly-Hayes M., Johnstone M. Quality and outcome measures for medical rehabilitation. Physical Medicine and Rehabilitation. W. B. Saunders Company. 1996: 239 - 253.
      10. Mahoney F., Barthel D. Functional evaluation: the Barthel Index. MD State Med. J. 1965; 14: 61 - 65.
      11. Токсикология. Национальное руководство под ред. Иванца Н. Н., Анохиной И. П., Винниковой М. А., М., ГЭОТАР-Медиа, 2008
     


    Full text is published :
    Livanov G.A., Shikalova I.A., Lodyagin A.N., Glushkov S.I. et al. FEATURES OF PHARMACOLOGICAL CORR ECTION OF ALCOHOLIC FATTY LIVER DISEASE IN PATIENTS WITH ACUTE ETHANOL INTOXICATION. Experimental and Clinical Gastroenterology Journal. 2016;129(05):45-50
    Read & Download full text

    1. State budget institution of higher professional education «Pavlov First Saint Petersburg State Medical University» under the Ministry of Public Health of the Russian Federation (St. Petersburg, Russian Federation)

    Keywords:steatosis,treatment,glycyrrhizin acid,ursodeoxycholic acid

    Abstract:Objective: To optimize the diagnostic and therapeutic approaches in polymorbid patients with fatty hepatosis in the practice of general practitioner. The medical tactics of treatment of polymorbidit patient with fatty liver, is considered in regards of the course of concomitant diseases, especially the cardiovascular system. Substantiates the necessity of determination of, in relation to the patient's prognosis, not only the degree of steatosis, but also the liver fibrosis stage changes, developing due to apoptosis of hepatocytes that leads to the progression of endothelial dysfunction A working version of the treatment of hepatic steatosis, designed to reduce progression of fatty degeneration, reducing the risk of steatohepatitis and fibrosis body changes is proposed in the paper. Ursodeoxycholic acid and glycyrrhizin are the most promising medication.

      1. Бабак О. Я., Колесникова Е. В. Участие печени в формировании метаболического синдрома и инсулинорезистентности. Состояние проблемы // Сучасна гастроентерологя. - 2006. - № 4 (30). - C. 8 - 12.
      2. Буеверов А. О. Жирная печень: причины и последствия // Практикующий врач. - 2002. - № 1. - С. 36 - 38.
      3. Буеверов А. О. Оксидативный стресс и его роль в повреждении печени // Рос. журн. гастроэнтерол. гепатол. колопроктол. - 2002. - Т. 12. - № 4. - С. 21 - 25.
      4. Драпкина О. М., Корнеева О. Н. Неалкогольная жировая болезнь печени и сердечно-сосудистый риск: влияние женского пола // Фарматека. - 2010. - № 15. - С. 1 - 5.
      5. Мехтиев С. Н., Зиновьева Е. Н. Современные аспекты патогенетического лечения неалкогольной жировой болезни печени // Эффективная фармакотерапия. Гастроэнтерология. - 2012. - № 4. - С. 24 - 28.
      6. Мехтиев С. Н., Мехтиева О. А. Жировая болезнь печени как фактор изменения риска сердечно-сосудистых «катастроф» у больных артериальной гипертензией // Лечащий врач. - 2015. - № 5. - С. 1 - 6.
      7. Мехтиев С. Н., Мехтиева О. А., Смирнова М. Н. Фиброз печени как показание для терапии у больных хроническими гепатитами // Эффективная фармакотерапия. Гастроэнтерология № 1. - 2015. - № 2. - С. 22 - 34.
      8. Мехтиев С. Н., Зиновьева Е. Н. Соколовский С. В. Эндотелиальная дисфункция как фактор прогрессирования неалкогольного стеатогепатита. Терапевтические подходы // Эффективная Фармакотерапия. - 2011. - № 2. - С. 36 - 44.
      9. Мехтиев С. Н., Степаненко В. В., Зиновьева Е. Н. Современные представления о фиброзе печени и методах его коррекции // Фарматека. - 2014. - № 6. - С. 80 - 87
      10. Павлов Ч. С., Глушенков Д. В., Ивашкин В. Т. Современные возможности эластометрии, фибро- и акти-теста в диагностике фиброза печени // Рос. журн. гастроэнтерол., гепатол. и колопроктол. - 2008. - № 4. - С. 43 - 52.
      11. Павлов Ч. С., Ивашкин В. Т., Шульпекова Ю. О., Золотаревский В. Б. Современные представления о патогенезе, диагностике и лечении фиброза печени // Рос. журн. гастроэнтерол., гепатол., колопроктол. - 2005. - Т. 15. - № 2. - С. 13 - 20.
      12. Рекомендации по ведению больных артериальной гипертонией с метаболическими нарушениями (под ред. И. Е. Чазова) // Кардиологический вестник. - 2014. - Т. 20. - № 1. - С. 1 - 58.
      13. Ройтберг Г. Е., Шархун О. О., Кондратова Н. В., Ушакова Т. И. Роль метаболического синдрома и его компонентов в патогенезе и прогрессировании неалкогольного стеатогепатита // Гепатология. - 2005. - № 5. - С. 30 - 36.
      14. Сторожаков Г. И., Ивкова А. Н. Патогенетические аспекты фиброгенеза при хронических заболеваниях печени // Клин. перспективы гастроэнтерологии, гепатологии. - 2009. - № 2. - С. 3 - 10.
      15. Шерлок Ш., Дули Дж. Заболевания печени и желчных путей: Практическое руководство. - М.: ГЭОТАР-МЕД, 2002. - 864 с.
      16. Aird WC. Endothelium as an organ system. Crit Care Med 2004;32 (5 Suppl):S271-279. [PubMed: 15118530].
      17. Bataller R., Brenner D. A. Liver fibrosis // J. Clin. Invest., 2005; 115 (2): 209 - 218.
      18. Bellentani S., Scaglioli F., Marino M., Bedogni G. Epidemiology of non - alcoholic fatty liver disease // Dig. Dis. - 2010. - № 28. - Р. 155 - 161.
      19. Casino P., Kilcoyne C. M., Quyyumi A. A., Hoeg J. M., Panza J. A. The role of nitric oxide in endothelium-dependent vasodilatation of hypercholesterolemic patients // Circulation. - 1993; 88: 2541 - 2547.
      20. Diehl A. M. Nonalcoholic steatosis and steatohepatitis IV: nonalcoholicfatty liver disease abnormalities in macrophage function and cytokines // Am. J. Physiol. - 2002;282: G1 - G5.
      21. Friedman S. Mechanisms of disease: mechanisms of hepatic fibrosis and therapeutic implications // Nat. Clin. Prac. Gastroenterol. Hepatol. - 2004; 1: 98 - 105.
      22. Frith J., Day C. P., Henderson E., Burt A. D., Newton J. L. Non-alcoholic fatty liver disease in older people // GERONTOLOGY. - 2009. - № 55 (6). - Р. 607 - 613.
      23. Hamaguchi M., Kojima T., Takeda N., et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease // World J. Gastroenterol. - 2007;13 (10):1579 - 84.
      24. Heil S. G., De Vriese A. S., Kluijtmans L. A., Mortier S., Den Heijer M., Blom H. J. The role of hyperhomocysteinemia in nitric oxide (NO) and endothelium-derived hyperpolarizing factor (EDHF) - mediated vasodilatation. Cell Mol Biol (Noisy-le-grand) 2004; 50 (8):911 - 916. [PubMed: 15704255].
      25. Ogawa E., Furusyo N., Toyoda K. et al. The longitudinal quantitative assessment by transient elastography of chronic hepatitis C patients treated with with pegylated interferon alpha-2d and ribavirin // Antiviral Res. - 2009; 83 (2): 127 - 134.
      26. Parsons C. J., Takashima M., Rippe R. A. Molecular mechanisms of hepatic fibrogenesis // J. Gastroenterol. Hepatol. - 2007; 22 (1):79 - 84.
      27. Poynard T., Zoulim F., Ratziu V. et al. Longitudinal assessment of histology surrogate markers (FibroTest - ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection // Am. J. Gastroenterol. - 200; 100: 1970 - 1980.
      28. Rockey D. C. Antifibrotic therapy in chronic liver disease // Clin. Gastroenterol. Hepatol. - 2005; 3: 95 - 107.
      29. Torres D. M., Williams C. D., Harrison S. A. Features, Diagnosis, and Treatment of Nonalcoholic Fatty Liver Disease / Cl. Gastroenter. Hepatol. 2012; 10: 837 - 858.
      30. Vane J., Annggard E. E., Botting R. M. Regulatory function of the vascular endothelium // N. Engl. J. Med. - 1990; 323: 27 - 36.
      31. Vernon G., Baranova A., Younossi Z. M. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and nonalcoholic steatohepatitis in adults // Aliment. Pharmacol. Ther. - 2011. № 34. - Р. 274 - 285.
      32. Wang Z. Y., Nixon D. W. Licorice and cancer // Nutr. Cancer. 2001. Vol. 39. № 1. P. 1 - 11.
      33. Zois C., Baltayiannis G., Karayiannis P., Tsianos E. Systematic review: hepatic fibrosis - regression with therapy // Aliment. Pharmacol. Ther. - 2008; 28: 1175 - 1187.
     


    Full text is published :
    Mehtiyev S.N., Mehtiyeva O.A. NEW PARADIGM CHALLENGES OF STEATOSIS TREATMENT IN THE PRACTICE THERAPIST. Experimental and Clinical Gastroenterology Journal. 2016;129(05):51-57
    Read & Download full text

    1. I. M. Sechenov First Moscow State Medical University (Moscow, Russian Federation)
    2. Pirogov Russian National Research Medical University (Moscow, Russian Federation)
    3. Moscow Regional Research Clinical Institute named after M. F. Vladimirsky (Moscow, Russian Federation)

    Keywords:birth defects,anorectal malformations,epidemiology,etiology,incidence

    Abstract:The review presents an analysis of current data on the epidemiology, etiology, clinical and genetic characteristics of congenital anorectal malformations (AM). According to international registers of congenital malformations prevalence of the AM varies from 2 to 5 per 10,000 births. There was no change in the prevalence over time of AM (absence of temporal trends). Most studies have indicated the predominance of males among patients with AM. Approximately 40 - 70% of patients with AM have congenital malformations of other organs and systems. The data on the participation of genetic and environmental factors in the origin of the AM. A brief clinical and genetic characteristics of the most common syndromes (association) with the AM.

      1. Hartman EE, Oort FJ, Aronson DC, Sprangers MA. Quality of life and disease-specific functioning of patients with anorectal malformations or Hirschsprung’s disease: a review. 2011 Arch Dis Child, 2011; 96:398 - 406.
      2. Stephens FD, Smith DE. Anorectal malformations in children. Chicago: Yearbook Publishers Inc. 1971; p 133.
      3. Stephens FD, Smith ED, Paoul NW. Anorectal malformations in children: update. March of Dimes Birth Defect Foundation Original series, 1988; vol. 24
      4. Stephens FD, Durham-Smith E. Classification, identification, and assessment of surgical treatment of anorectal anomalies. Pediatr Surg Int, 1986; 1: 200 - 205.
      5. Pena A. Anorectal malformations. Semin Pediatr Surg. 1995;4:35 - 47
      6. Ленюшкин А. И. Колопроктология детского возраста. Руководство для врачей. Медицина. 1999. - 365 С.
      7. Smith ED. Incidence, frequency of types and aetiology of anorectal malformations. Birth Defects Orig Artic, 1988; Ser 24 (4):231 - 246
      8. Harris J, Kallen B, Robert E. Descriptive epidemiology of alimentary tract atresia. Teratology, 1995; 52:15 - 29.
      9. A Cuschieri and EUROCAT Working Group. Descriptive Epidemiology of Isolated Anal Anomalies: A Survey of 4.6 Million Birth in Europe. Am J Med Genet, 2001; 103: 207 - 15.
      10. Forrester MB, Merz RD. Risk of Selected Birth Defects with Prenatal Illicit Drug Use, Hawaii, 1986 - 2002. J Toxicol Environ Health A. 2007; 70: 7 - 18.
      11. Sun G, Xu ZM, Laing JF, LiL, Tang DX. Twelve-year prevalence of common neonatal congenital malformations in Zhejiang Province, China. World J Pediatr, 2011; 7: 331 - 336
      12. Almaramhy, Hamdi H. Incidence and spectrum of anorectal malformations in Western Saudi Arabia. Saudi Medical Journal, 2012: Vol. 33, No 12:
      13. Stoll C, Alembik Y, Roth MP, Dott B. Risk factors in congenital analatresias. Ann Genet. 1997; 40: 197 - 204.
      14. Yang JH, et al. A multi-center study for birth defect monitoring. Arch Pediatr Adolesc Med, 2004; 155: 587 - 591
      15. Landau, D., Mordechai, J., Karplus, M., Carmi, R. Inheritance of familial congenital isolated anorectal malformations: case report and review. Am. J. Med. Genet, 1997; 71: 280 - 282.
      16. Falcone RA Jr, MA Levitt, A Peña, M Mates, Increased heritability of certain types of anorectal malformations. J Pediatr Surg, 2007; 42, 124 - 8.
      17. Wijers CH, de Blaauw I, Marcelis CL, et al. Research perspectives in the etiology of congenital anorectal malformations using data of the International Consortium on Anorectal Malformations: evidence for risk factors across different populations. Pediatr Surg Int, 2010; 26:1093 - 1099
      18. Zhang J, Zhang ZB, Gao H, et al. Down-regulation of SHH/BMP4 Signalling in Human Anorectal Malformations. J Int Med Res, 2009; 37:1842 - 1850
      19. Carter TC, Kay DM, Browne ML, et al. Anorectal atresia and variants at predicted regulatory sites in candidate genes. AnnHumGenet, 2013; 77:31 - 46
      20. Moore SW, Zaahl MG. Association of endothelin-beta receptor (EDNRB) gene variants in anorectal malformations. J Pediatr Surg. 2007 Jul; 42 (7):1266 - 70
      21. Zhang T, Tang XB, Wang LL, et al. Mutations and down-regulation of CDX1 in children with anorectal malformations. Int J MedSci, 2013; 10:191 - 197
      22. Lickert H., Domon C., Huls G., Wehrle C., Duluc I., Clevers H. et al. Wnt/ (beta) - catenin signaling regulates the expression of the homeobox gene Cdx1 in embryonic intestine. Development, 2000; 127: 3805 - 3813
      23. Wong EH, Cui L, Ng CL, et al. Genome-wide copy number variation study in anorectal malformations. Hum Mol Genet, 2013; 22: 621 - 631
      24. Wijers CH, van Rooij IA, Marcelis CL et al. Genetic and nongenetic etiology of nonsyndromic anorectal malformations: a systematic review. Birth Defects Res C Embryo Today 2014;102:382 - 400.
      25. Hay S, Barbano H. Independent effects of maternal age and birth order on the incidence of selected congenital malformations. Teratology 1972; 6:271 - 279.
      26. Myers MF, Li S, Correa-Villaseñor A, et al. Folic acid supplementation and risk for imperforate anus in China. Am J Epidemiol 2001;154:1051 - 1056.
      27. van Rooij IA, Wijers CH, Rieu PN, et al. Maternal and Paternal Risk Factors for anorectalMalformations: A Dutch Case-Control Study. Birth Defects Res A ClinMolTeratol, 2010; 88, 152 - 8
      28. Wijers CHW, van Rooij IALM, Bakker MK, et al. Anorectal malformations and pregnancy-related disorders: a registry-based case-control study in 17 European regions. BJOG 2013; 120:1066 - 1074.
      29. Forrester MB, Merz RD. Descriptive epidemiology of anal atresia in Hawaii, 1986 - 1999. Teratology 2002; 66 Suppl 1: S12-16.
      30. Miller EA, Manning SE, Rasmussen SA, et al. Maternal exposure to tobacco smoke, alcohol and caffeine, and risk of anorectal atresia: National Birth Defects Prevention Study 1997 - 2003. Paediatr Perinat Epidemiol, 2009; 23:9 - 17.
      31. Källén B, Finnström O, Nygren KG, et al. In vitro fertilization (IVF) in Sweden: risk for congenital malformations after different IVF methods. Birth Defects Res A Clin Mol Teratol, 2005; 73:162 - 169.
      32. Midrio P, Nogare CD, Di GE, et al. Are congenital anorectal malformations more frequent in newborns conceived with assisted reproductive techniques? Reprod Toxicol 2006; 22:576 - 577.
      33. Reefhuis J, Honein MA, Schieve LA, et al. Assisted reproductive technology and major structural birth defects in the United States. Hum Reprod., 2009; 24:360 - 366.
      34. Zwink N, Jenetzky E, Schmiedeke E, et al. Assisted reproductive techniques and the risk of anorectal malformations: a German case-control study. Orphanet J Rare Dis, 2012; 7:65.
      35. Waller DK, Shaw GM, Rasmussen SA, et al. Prepregnancy obesity as a risk factor for structural birth defects. Arch Pediatr Adolesc Med, 2007; 161:745 - 750.
      36. Frías JL, Frías JP, Frías PA, et al. Infrequently studied congenital anomalies as clues to the diagnosis of maternal diabetes mellitus. Am J Med Genet. A, 2007; 143A: 2904 - 2909.
      37. Correa A, Gilboa SM, Besser LM, et al. Diabetes mellitus and birth defects. Am J Obstet Gynecol., 2008; 199:237 - 239.
      38. Feldkamp ML, Meyer RE, Krikov S, et al. Acetaminophen use in pregnancy and risk of birth defects: findings from the National Birth Defects Prevention Study. Obstet Gynecol 2010; 115:109 - 115.
      39. Broussard CS, Rasmussen SA, Reefhuis J, et al. Maternal treatment with opioid analgesics and risk for birth defects. Am J Obstet Gynecol 2011; 204:314 e311-311.
      40. van Gelder MM, Roeleveld N, Nordeng H. Exposure to non-steroidal anti-inflammatory drugs during pregnancy and the risk of selected birth defects: a prospective cohort study. PLoS One 2011; 6: e221-274.
      41. Crider KS, Cleves MA, Reefhuis J, et al. Antibacterial medication use during pregnancy and risk of birth defects: National Birth Defects Prevention Study. Arch Pediatr Adolesc Med, 2009;163:978 - 985.
      42. Reis M, Källén B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med 2010; 40:1723 - 1733.
      43. Bonnot O, Vollset SE, Godet PF, et al. Maternal exposure to lorazepam and anal atresia in newborns: results from a hypothesis-generating study of benzodiazepines and malformations. JClin Psychopharmacol, 2001; 21:456 - 458.
      44. Eros E, Czeizel AE, Rockenbauer M, et al. A population-based case-control teratologic study of nitrazepam, medazepam, tofisopam, alprazolum and clonazepam treatment during pregnancy. Eur J Obstet Gynecol Reprod Biol 2002; 101:147 - 154.
      45. Czeizel AE, Eros E, Rockenbauer M, et al. Short-Term Oral Diazepam Treatment during Pregnancy: A Population-Based Teratological Case-Control Study. Clin Drug Investig 2003; 23:451 - 462.
      46. Czeizel AE, Rockenbauer M, Sorensen HT, et al. A population-based case-control study of oral chlordiazepoxide use during pregnancy and risk of congenital abnormalities. Neurotoxicol Teratol, 2004;26:593 - 598.50
      47. Kjaer D, Horvath-Puhó E, Christensen J, et al. Use of phenytoin, phenobarbital, or diazepam during pregnancy and risk of congenital abnormalities: a case-time-control study. Pharmacoepidemiol Drug Saf 2007; 16:181 - 188.
      48. Herdt-Losavio ML, Lin S, Chapman BR, Hooiveld M, et al. Maternal occupation and the risk of birth defects: an overview from the National Birth Defects Prevention Study. Occup Environ Med., 2010; 67, 58 - 66. doi: 10.1136/oem. 2009.048256
      49. Yuan P, Okazaki I, Kuroki Y. Anal atresia: effect of smoking and drinking habits during pregnancy. Jpn J Hum Genet. 40, 1995; 327 - 32
      50. Zwink et al. Orphanet Journal of Rare Diseases, 2011; 6:25http://www.ojrd.com/content/6/1/25Page 15 of 16
      51. Honein MA, Paulozzi LJ, Watkins ML, Maternal smoking and birth defects: validity of birth certificate data for effect estimation. Public Health Rep., 2001; 116,327 - 35.
      52. Jenetzky E, Prevalence estimation of anorectal malformations using German diagnosis related groups system. PediatrSurgInt, 2007; 23:1161 - 1165
      53. Holschneider A, Hutson J, Pen˜a A, Beket E, et al. Preliminary report on theInternational Conference for the Development of Standards forthe Treatment of Anorectal Malformations. J PediatrSurg, 2005; 40:1521 - 1526
      54. Marcelis C, de Blaauw I, Brunner H. Chromosomal anomalies in the etiology of anorectal malformations: A review. Am J Med Genet Part A, 2011; 9999: 1 - 13 www.omim.org
      55. Sam W Moore. Associations of anorectal malformations and related syndromes. Pediatr Surg Int, 2013; 29, 665 - 676
     


    Full text is published :
    Vydrych Yu.V., Demikova N.S., Filyushkin Yu.N., Kalinenkova S.G. et al. EPIDEMIOLOGICAL, CLINICAL AND GENETIC CHARACTERISTICS OF ANORECTAL MALFORMATIONS (REVIEW). Experimental and Clinical Gastroenterology Journal. 2016;129(05):58-64
    Read & Download full text

    1. State Budget Educational Institution of Higher Professional Education (SBEI HPE) «A. I. Evdokimov Moscow State University of Medicine and Dentistry Ministry of Healthcare of Russia» (Moscow, Russian Federation)

    Abstract:The paper reflects the issues of pathogenesis of the chronic liver diseases (CLD). The role of the cell membrane lipid peroxidation as well as oxidative stress and fibrosis formation in the development and progression of liver lesions of various aetiologies. are represented in details. Particular attention is given to the justification of pathogenetic approaches to the treatment of liver disease. Presented the evidence base of successful application of the standardized silymarin as a part of the drug Legalon in the CLD of different etiology.

      1. Барабой В. А., Сутковой Д. А. Окислительно-антиоксидантный гомеостаз в норме и патологии / Под. ред. акад. АМН Украины Ю. А. Зозули. - К.: Чернобыльинтеринформ, 1997. - Ч. 1, 2.
      2. Васильева Е. М., Баканов М. И., Поддубная А. Е., Шор Т. А. Перекисное окисление липидов при неврологической патологии у детей // Клиническая лабораторная диагностика. - 2005. - № 2. - С. 8 - 12.
      3. Голованова Е. В. Механизмы фиброзообразования при хронических заболеваниях печени и возможности антифибротической терапии. Consilium Medicum, - 2014. № 8 (том 16), стр. 52 - 59.
      4. Голованова Е. В. Технология проведения пункционной биопсии печени (рекомендации НОГР). «Экспериментальная и клиническая гастроэнтерология», № 5, 2009, стр. 140 - 144.
      5. Голованова Е. В., Логинов А. Ф. Фиброз при хронических заболеваниях печени. Возможности антифибротической терапии. Учебно-методическое пособие для врачей. Институт усовершенствования врачей ФГБУ «НМХЦ им. Н. И. Пирогова» Минздрава России, Москва, 2013. С. 30.
      6. Зозуля Ю. А., Барабой В. А., Сутковой Д. А. Свободнорадикальное окисление и антиоксидантная защита при патологии головного мозга. - М.: Знание-М., 2000. - 9 с.
      7. Казимирко В. К., Мальцев В. И. Aнтиоксидантная система и ее функционирование в организме человека // http: www.health-ua.com /2004
      8. Коровина Н. А., Захарова И. Н., Обыночная Е. Г. Применение антиоксидантов в педиатрической практике // http: media consilium/03_09/ Feb - 2004.
      9. Курашвили В. А., Майлэм Л. Новые возможности предотвращения оксидативного стресса // Журнал натуральной медицины. - 2001. - № 1. - С. 7 - 14.
      10. Лазебник Л. Б., Радченко В. Г., Голованова Е. В. и соавт. Неалкогольная жировая болезнь печени: клиника, диагностика, лечение. Клинические рекомендации НОГР. - Экспериментальная и клиническая гастроэнтерология - 2015. - № 119 (7) - C. 85 - 96.
      11. Лещинский Л. Д. Обоснование и опыт применения ряда ингибиторов перекисного окисления липидов у больных ишемической болезнью сердца // ТОП-Медицина. - 1998. - № 4. - С. 17 - 21.
      12. Марри Р., Греннер Д., Мейес П., Родуэлл В. Биохимия человека. - М., 1993. - Т. 1 - 2. - 779 с.
      13. Овсянникова Л., Носач Е. Антиоксидантные препараты: проблема выбора // Doctor. - 2003. - № 1. - С. 74 - 76.
      14. Суханова Г. А., Серебров В. Ю. Биохимия клетки. - Томск: Чародей, 2000. - С. 91 - 142.
      15. Щербаков А. Е. Исследование показателей перекисного окисления липидов и антиоксидантной системы в комплексе мероприятий вторичной профилактики инсультов // http: www.rusmedserv.com/ 2000
      16. Яворская В. А, Малахов В. А., Белоус А. М. Интенсивность процессов перекисного окисления липидов и активность антиоксидантных ферментов в эритроцитах при начальных формах сосудистых заболеваний головного мозга // Неврологический вестник. - 1995. - Т. XXVII, вып. 3 - 4. - С. 15 - 17.
      17. Afdhal N. H., Nunes, D. Evaluation of liver fibrosis: a concise review. // Am. J. Gastroenterol. 2004. - 99:1160 - 1174.
      18. Albanis E., Friedman S. L. Hepatic fibrosis. Pathogenesis and principles of therapy. // Clin. Liver Dis. 2001;5:315 - 334
      19. Albano E, Mottaran E, Vidali M, et al. Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis. Gut. 2005; 54 (7): 987 - 93.
      20. Allard JP, Aghdassi E, Mohammed S, et al. Nutritional assessment and hepatic fatty acid composition in nonalcoholic fatty liver (NAFLD):a cross-sectional study. J Hepatol. 2008; 48 (2): 300 - 7.
      21. Barreyro FJ, Kobayashi S, Bronk SF, et al. Transcriptional regulation of Bim by FoxO3a mediates hepatocyte lipoapoptosis. J Biol Chem. 2007; 282 (37): 27141 - 54.
      22. Bataller R., Brenner D. A. Hepatic stellate cells as a target for the treatment of liver fibrosis. // Semin. Liver Dis. 2001.21:437 - 451
      23. Benyon R. C., Iredale, J. P. Is liver fibrosis reversible? // Gut. 2000.46:443 - 446
      24. Caballero F, Fernández A, Matías N, et al. Specific contribution of methionine and choline in nutritional nonalcoholic steatohepatitis: impact on mitochondrial S-adenosyl-L-methionine and glutathione. J Biol Chem. 2010; 285 (24): 18528 - 36.
      25. Chalasani N, Deeg MA, Crabb DW. Systemic levels of lipid peroxidation and its metabolic and dietary correlates in patients with nonalcoholic steatohepatitis. Am J Gastroenterol. 2004; 99 (8): 1497 - 502.
      26. Chavin KD, Yang S, Lin HZ, et al. Obesity induces expression of uncoupling protein-2 in hepatocytes and promotes liver ATP depletion. J Biol Chem. 1999; 274: 5692 - 700.
      27. Dehmlow С., Erhard J., Groot H. Inhibition of Kupffer cell functions as an explanation for the hepatoprotective properties of Silibinin //Life Sci. 58, 749 - 754, 1996
      28. Echtay KS, Murphy MP, Smith RA, et al. Superoxide activates mitochondrial uncoupling protein 2 from the matrix side. Studies using targeted antioxidants. J Biol Chem. 2002; 277.
      29. Esterbauer H., Gebicki J., Puhl H., Jurgens G. The role of lipid peroxidation and antioxidants in oxidative modification of LDL // Free Radic. Biol. Med. - 1992. - № 13. - P. 341 - 390.
      30. Ferenci et al. // J. Hepatol. 1989. - № 9, 105 - 113,
      31. Frei B., Stocker R., Ames B. N. Antioxidant defenses and lipid peroxidation in human blood plasma // Proc. Natl. Acad. Sci. USA. - 1988. - № 85. - Р. 9748 -9752.
      32. Geerts A. History, heterogeneity, developmental biology, and functions of quiescent hepatic stellate cells. // Semin. Liver Dis. 2001.21:311 - 335.
      33. Halliwell B. O., Gutteridge J. M. C. Free radicals in biology and medicine. - Oxford: Clarendon Press, 1989.
      34. Hardwick JP, Osei-Hyiaman D, Wiland H, et al. PPAR/RXR regulation of fatty acid metabolism and fatty acid ω-hydroxylase (CYP4) isozymes: Implications for prevention of lipotoxicity in fatty liver disease. PPAR Res. 2009: 9527 - 34.
      35. Ikura Y, Ohsawa M, Suekane T, et al. Localization of oxidized phosphatidylcholine in nonalcoholic fatty liver disease: impact on disease progression. Hepatology. 2006; 43 (3): 506 - 14.
      36. Jia et al., Hepatology 28, 546A, 1998
      37. Kodama Y, Brenner DA. C-Jun N-terminal kinase signaling in the pathogenesis of nonalcoholic fatty liver disease: multiple roles in multiple steps. Hepatology. 2009; 49 (1): 6 - 8.
      38. Krinsky N. L. Membrane antioxidants // Ann. NY. Acad. Sci. - 1988. - № 551. - Р. 17 - 33.
      39. Ladas EJ, Kroll DJ, Oberlies NH, Cheng B, Ndao DH, Rheingold SR, Kelly KM. A randomized, controlled, double-blind, pilot study of milk thistle for the treatment of hepatotoxicity in childhood acute lymphoblastic leukemia (ALL). // Cancer. 2010;116 (2):506 - 13
      40. Leclercq IA, Farrell GC, Field J, et al. CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis. J Clin Invest. 2000; 105:1067 - 75.
      41. Lieber CS. The discovery of the microsomal ethanol oxidizing system and its physiologic and pathologic role. Drug Metab Rev. 2004; 36 (3-4): 511 - 29.
      42. Madan K, Bhardwaj P, Thareja S, et al. A. Oxidant stress and antioxidant status among patients with nonalcoholic fatty liver disease (NAFLD). J Clin Gastroenterol. 2006; 40 (10): 930 - 35.
      43. Malhi H, Gores GJ. Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease. Semin Liver Dis. 2008; 28 (4): 360 - 9.
      44. McClain CJ, Mokshagundam SP, Barve SS, et al. Mechanisms of non-alcoholic steatohepatitis. Alcohol. 2004; 34: 67 - 79.
      45. Mourelle et al., Fundam. // Clin. Pharmacol. 3, 183 - 191,1989
      46. Nair J, Srivatanakul P, Haas C, et al. High urinary excretion of lipid peroxidation-derived DNA damage in patients with cancer-prone liver diseases. Mutat Res. 2010; 683: 23 - 8.
      47. Payer B. A., Reiberger T., Rutter K. Successful HCV eradication and inhibition of HIV replication by intravenous silibinin in an HIV - HCV coinfected patient //Journal of Clinical Virology 49 (2010) 131 - 133
      48. Pessayre D. Role of mitochondria in non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2007; 22 suppl 1: 20 - 7.
      49. Ramasamy K, Agarwal R. //Cancer Lett. 2008;269 (2):352 - 62
      50. Robertson G, Leclercq I, Farrell GC. Nonalcoholic steatosis and steatohepatitis. II. Cytochrome P-450 enzymes and oxidative stress. Am J Physiol Gastrointest Liver Physiol. 2001; 281 (5): 1135 - 9.
      51. Rockey D. C. // Clin Gastroenterol Hepatol 2005; 3: 95 - 107.
      52. Sanyal AJ, Campbell-Sargent C, Mirshahi F, et al. Non alcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology. 2001; 120 (5): 1183 - 92.
      53. Schuppan D., Pinzani M. Anti-fibrotic therapy: Lost in translation? //J. of Hepatology, Suppl. 1 (Vol. 56). - 2012. - P. S56-S74.
      54. Schuppan, Z. //Allg. Med. 74, 577 - 584, 1998
      55. Seeff LB, Curto TM, Szabo G. et al. Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. //Hepatology 2008;47:605 - 612.
      56. Seki S, Kitada T, Sakaguchi H. Clinicopathological significance of oxidative cellular damage in non-alcoholic fatty liver diseases. Hepatol Res. 2005; 33 (2): 132 - 4.
      57. Syn WK, Yang L, Chiang DJ, et al. Genetic differences in oxidative stress and inflammatory responses to dietinduced obesity do not alter liver fibrosis in mice. Liver Int. 2009; 29 (8): 1262 - 72.
      58. Weltman MD, Farrell GC, Hall P, et al. Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis. Hepatology. 1998; 27 (1): 128 - 33.
     


    Full text is published :
    Golovanova E.V. THE PATHOGENETIC APPROACHES TO THE CHRONIC LIVER DISEASES TREATMENT. Experimental and Clinical Gastroenterology Journal. 2016;129(05):65-73
    Read & Download full text

    1. The First Moscow State Medical University (Moscow, Russian Federation)

    Abstract:The purpose of the review is to analyze modern data on pathogenesis, principles of treatment and future prospects treatment of nonalcoholic fatty liver disease (NAFLD). Modern ideas about the role of insulin resistance, oxidative stress gene polymorphisms in the pathogenesis of disease progression. This has led in recent years to a new strategy of treatment of the disease. Examines the role of physical load, modified diet, the weight loss. Substantiates the primary role of the use of insulin sensitizers, and agents with cytoprotective and antioxidant effect. The lack of the only effective drug for the treatment of NAFLD justifies the appropriateness of the appointment of combination therapy with exposure to various aspects of the pathogenesis. Elaborates on new drugs under clinical study.

      1. Драпкина О. М., Гацолаева Д. С., Ивашкин В. Т. Неалкогольная жировая болезнь печени как компонент метаболического синдрома. //Российские медицинские вести, 2010, том 15, 2. с. 72 - 78
      2. Драпкина О. М., Ивашкин В. Т. Эпидемиологические особенности неалкогольной жировой болезни печени в России. //Российский журнал гастроэнтерологии гепатологии, колопроктологии. 2014, том 24, 4. с. 32 - 38
      3. Ивашкин В. Т., Драпкина О. М. Маев И. В. и др. Рапространенность неалкогольной жировой болезни печени у пациентов амбулаторно-поликлинической практики в Российской Федерации: результаты исследования DIREG2. //Российский журнал гастроэнтерологии гепатологии, колопроктологии. 2015, том 6, с. 31 - 41
      4. McCullough A. J: Update on nonalcoholic fatty liver disease. J. Clin. Gastroenterol, 2002; 34: 255 - 262
      5. Ludwig J. Viggiano RT., McGill DB., Oh BJ. Nonalcoholic steatohepatitis: Mayo experiences with a hitherto unnamed disease. Mayo Clin Proc. 1980; 55: 434 - 438
      6. Browning JD, et al: Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology, 2004; 40:1387 - 1395
      7. Kotronen A. Johansson L. E., Johansson L. M. et. al. A common variant in PNPLA3, which encodes adiponutrin is associated with liver fat content in humans. Diabetologia. 2009; 52 (6): 1056 - 60
      8. Лазебник Л. Б., Звенигородская Л. А. Метаболический синдром и органы пищеварения. - М. Анахарсис, 2009. 184с
      9. de Marco R, Locatelli F, Zoppini G, et. al. Causespecific mortality in type 2 diabetes. The Verona Diabetes Study. Diabetes Care, 1999; 22:756 - 761
      10. Adams LA, Harmsen S, St Sauver JL, et al. Nonalcoholic fatty liver disease increases risk of death among patients with diabetes: a community-based cohort study. Am. J. Gastroenterol. 2010;105:1567 - 1573.
      11. Zoppini G, Fedeli U, Gennaro N, et al. Mortality from chronic liver diseases in diabetes. Am. J. Gastroenterol. 2014;109:1020 - 1025.
      12. Dixon JB, Bhathal PS, Hughes NR, O’Brien PE. Nonalcoholic fatty liver disease: improvement in liver histological analysis with weight loss. Hepatology 2004;39:1647 - 1654.
      13. Lassailly G, Caiazzo R, Buob D, et al. Effects of bariatric surgery on severe liver injury in morbid obese patients with proven NASH: a prospective study. Hepatology, 2014;60:305A.
      14. Moschen AR, Molnar C, Geiger S, et al. Anti-inflammatory effects of excessive weight loss: potent suppression of adipose interleukin 6 and tumour necrosis factor expression. Gut, 2010; 59:1259 - 1264.
      15. Kistler KD, Brunt EM, Clark JM, et al. Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease. Am. J. Gastroenterol. 2011;106:460 - 468.
      16. Fealy CE, Haus JM, Solomon TP, et al. Short-term exercise reduces markers of hepatocyte apoptosis in nonalcoholic fatty liver disease. J. Appl. Physiol. 1985;2012:1 - 6.
      17. Yu JG, Javorschi S, Hevener AL, et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 2002;51:2968 - 2974.
      18. Neuschwander-Teri B. A., et. al. Improved alcoholic steatohepatitis after 48 weeks of treatment the PPAR_γ- ligand rosiglitazone. Hepatology, 2003;38: 1008 - 1017
      19. Ratziu V, Charlotte F, Bernhardt C, et al. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial. Hepatology, 2010;51:445 - 453.
      20. Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med. 2010;362:1675 - 1685.
      21. Sanyal AJ, Brunt EM, Kleiner DE, et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis. Hepatology, 2011;54:344 - 353.
      22. Belfort R, Harrison SA, Brown K, et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N. Engl. J. Med. 2006;355:2297 - 2307
      23. Aithal GP, Thomas JA, Kaye PV, et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology, 2008;135:1176 - 1184.
      24. Uygun A., Kadayifci A., Isik At. et. al. Metformin in the treatment of patients with non-alcoholic steatohepatitis. Aliment. Pharmacol. Ther. 2004:19:537 - 544
      25. Lavine JE, Schwimmer JB, Van Natta ML, et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA, 2011;305:1659 - 1668
      26. Bhalla K, Hwang BJ, Dewi RE, et al. Metformin prevents liver tumorigenesis by inhibiting pathways driving hepatic lipogenesis. Cancer Prev. Res. (Phila) 2012;5:544 - 552.
      27. Chen HP, Shieh JJ, Chang CC, et al. Metformin decreases hepatocellular carcinoma risk in a dose-dependent manner: population-based and in vitro studies. Gut, 2012;62:606 - 615
      28. Watanabe M, Houten SM, Wang L, et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest 2004;113:1408 - 1418
      29. Wagner M, Zollner G, Trauner M. Nuclear bile acid receptor farnesoid X receptor meets nuclear factor-kappaB: new insights into hepatic inflammation. Hepatology, 2008;48:1383 - 1386.
      30. Wang YD, Chen WD, Wang M, et al. Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. Hepatology 2008; 48:1632 - 1643
      31. Mudaliar S, Henry RR, Sanyal AJ, et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology, 2013; 145:574 - 582
      32. Staels B, Rubenstrunk A, Noel B, et al. Hepato-protective effects of the dual PPARalpha/delta agonist GFT505 in rodent models of NAFLD/NASH. Hepatology, 2013;58:1941 - 1952.
      33. Cariou B, Hanf R, Lambert-Porcheron S, et al. Dual peroxisome proliferator-activated receptor alpha/delta agonist GFT505 improves hepatic and peripheral insulin sensitivity in abdominally obese subjects. Diabetes Care, 2013;36:2923 - 2930
      34. Armstrong MJ, Houlihan DD, Rowe IA, et al. Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program. Aliment. Pharmacol. Ther. 2013;37:234 - 242.
      35. Armstrong MJ, Hull D, Guo K, et al. Effect of liraglutide on adipose insulin resistance and hepatic de-novo lipogenesis in non-alcoholic steatohepatitis: substudy of a phase 2, randomised placebocontrolled trial. Lancet, 2014;383: S21.
      36. Lieber C. S. Alcoholic liver diseas: new in sigths in pathogenesis lead to new treatment//Hepatology. - 2000. - Vol. 32, suppl. 1. - P. 113 - 128.
      37. Sun Cunxu, Zheng Xianling, Tan Zenghuan, Clinical Observation on Polyene Phosphatidyl Choline and Metformin in the Treatment of Type 2 Diabetes and Non-alcoholic Fatty Liver Disease. Clinical Focus, September 5, 2008, Vol. 23, No. 17
      38. Подымова С. Д., Довлетшина И. В. Эффективность применения α-липоевой кислоты (берлитиона) у больных неалкогольным стеатогепатитом Ж. «Экспериментальная и клиническая гастроэнтерология» 2008, N5
      39. Soden JS, Devereaux MW, Haas JE, et al. Subcutaneous vitamin E ameliorates liver injury in anin vivo model of steatocholestasis. Hepatology 2007;46:485 - 495
      40. Daryani N. E., Mirmomen S., Farahvash M. J. et al. Vitamin E the treatment of Patients with NASH: Placebo-controlled Double - Blindstady//GUT, International Journal of Gastroenterology and Hepatology. - 10th UEGW. - Geneva, 2002. - A (15).
      41. Ratzui V., De Ledinghen V., Oberti F. et. al. A randomized controlled trial of higy-dosei ursodeoxycholic asid for nonalcoholic steatohepatitis. J. Hepatol. 2011; 54 (5); 1011 - 19
      42. Leuschner U. F., Lindenthal B., Herrmann G., et. al. Higy-dose ursodeoxycholic asid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. J. Hepatol. 2010; 52 (2); 472 - 79
      43. Haedrich M.,Dufour JF. UDCA for End of the story. J. Hepatol. 2011; 54 (5); 856 - 58.
      44. Adams LA, et al: A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am. J. Gastroenterol, 2004; 99:2365 - 2368.
      45. Satapathy SK, et al: Beneficial effects of tumor necrosis factor-alpha inhibition by pentoxifylline on clinical, biochemical, and metabolic parameters of patients with nonalcoholic steatohepatitis. Am. J. Gastroenterol. 2004; 99:1946 - 1952.
     


    Full text is published :
    Podymova S.D. THE MODERN VIEW ON PATHOGENESIS AND TREATMENT OF NONALCOHOLIC FATTY LIVER DISEASE. Experimental and Clinical Gastroenterology Journal. 2016;129(05):74-82
    Read & Download full text

    1. MultiCare Medical Center of Bank of Russia (Moscow, Russian Federation)
    2. Federal State Institution of Additional professional education «Central State Medical Academy» of President Administration (Moscow, Russian Federation)
    3. State Institution «Psychiatric hospital № 5» of Moscow Department of Health (Moscow, Russian Federation)

    Keywords:Emotional burnout syndrome,health professionals,predictors,prophylaxis

    Abstract:Working in conditions of physical and psychological overload, occupational hazard makes health workers vulnerable to the development of burnout syndrome. Currently, 67.6% of physicians in Russia suffer from emotional burnout syndrome. This syndrome is characterized by a certain symptoms, which have their predictors. Prevention and treatment of emotional burnout syndrome - a complex problem that can be solved with the participation of heads of medical institutions, full-time psychologists and psychotherapists with the direct involvement of health professionals

      1. Ананьев Б. Г. Человек как предмет познания. - Л.: Изд-во ЛГУ, 1968. - 339 с.
      2. Березовская Л. Г. К вопросу критериев риска развития синдрома «эмоционального выгорания» / Л. Г. Березовская, В. Ю. Слабинский, С. А. Подсадный // Проблемы исследования синдрома «выгорания» и пути его коррекции у специалистов «помогающих» профессий (в медицинской, психологической и педагогической практике): сб. науч. ст. / под ред. В. В. Лукьянова, С. А. Подсадного; Курский Гос. Ун-т. - Курск, 2007. - С. 17 - 19.
      3. Бойко В. В. Энергия эмоций в общении: взгляд на себя и других. - М., 1996. - 472 с.
      4. Диагностика эмоционального выгорания личности (В. В. Бойко) / Фетискин Н. П., Козлов В. В., Мануйлов Г. М. Социально-психологическая диагностика развития личности и малых групп. - М., Изд-во Института Психотерапии. 2002. - 490 с.
      5. Международная Классификация болезней (10-й пересмотр). Классификация психических и поведенческих расстройств / под ред. Ю. Л. Нуллера, С. Л. Циркина; ВОЗ. - СПб.: Оверлайд, 1994. - 300 с.
      6. Распространенность Синдрома эмоционального выгорания у врачей различных специальностей / В. Л. Малыгин, А. Б. Искандирова, Е. Е. Пахтусова, Д. В. Шевченко // Проблемы исследования синдрома «выгорания» и пути его коррекции у специалистов «помогающих» профессий (в мед., псих. и педаг. практике: сб. науч. ст. / Под ред. В. В. Лукьянова, С. А. Подсадного; Курск. гос. ун-т, С.-Петерб. гос. мед. акад. им. И. И. Мечникова. - Курск: Изд-во Курск. гос. ун-та, 2007. - С. 108 - 110.
      7. Borritz, R. Rugulies, K. B. Christensen, E. Villadsen, T. S. Kristensen Burnout as a predictor of self-reported sickness absence among human service workers: Prospective findings from three year follow up of the // PUMA study Occupational and Environmental Medicine - 2006. - V 63: - P. 98 - 106.
      8. Duijts, I. Kant, G. M. Swaen, P. A. van den Brandt, M. P. Zeegers A meta-analysis of observational studies identifies predictors of sickness absence // Journal of Clinical Epidemiology - 2007. - V 60: - P. 1105 - 1115.
      9. Gómez-Gascón, J. Martín-Fernández, M. Gálvez-Herrer, E. Tapias-Merino, M. Beamud-Lagos, J. C. Mingote-Adán, Grupo EDESPROAP-Madrid Effectiveness of an intervention for prevention and treatment of burnout in primary health care professionals // BMC Family Practice - 2013. - V 14: - P. 173.
      10. Lee R. T., Seo B., Hladkyj S., Lovell B. L., Schwartzmann L. Correlates of physician burnout across regions and specialties: A meta-analysis // Human Resources for Health - 2013. - V 11: - P. 48 - 90.
      11. Maslach C., Goldberg J. Preventionof bumout: New perspectives // Applied and Preventive Psychology. - 1998. - V. 7. - P. 63 - 74.
      12. Maslach С., Jackson S. E. Maslach burn-out inventory Consulting Psychologists Press, Palo Alto, 1986.
      13. Shanafelt T. D., Balch C. M., Bechamps G. J., Russell T., Dyrbye L., Satele D., et al. Burnout and career satisfaction among American surgeons // Annals of Surgery- 2009. - V 14: - P. 463 - 471.
      14. Wallace J. E., Lemaire J. B., Ghali W. A. Physician wellness: A missing quality indicator Lancet- 2009. - V 374 (9702): - P. 1714 - 1721.
     


    Full text is published :
    Elfimova E.V., Elfimov M.A., Berezkin A.S. HOW TO PREVENT EMOTIONAL BURNOUT SYNDROME IN HEALTH PROFESSIONALS?. Experimental and Clinical Gastroenterology Journal. 2016;129(05):83-87
    Read & Download full text

    1. Perm State Medical University. Acad. E. A. Wagner (Perm, Russian Federation)

    Keywords:polymorbidity,comorbidity,ulcer disease,peptic ulcerliver,biliary tract,history,surgery

    Abstract:The Purpose. To present the history of surgical gastroenterology in Perm krai. Materials and methods. Narrative, historical, genetic, comparative and structural. Results. In the early 20th century the main method of surgical treatment of peptic ulcer was gastroenteroanastomosis. A significant number of recurrences resulted to distal gastrectomy implementation in the 30s in the Clinic of hospital surgery of Perm medical institute, led by professor M. V. Shats. It was also performed in major cities of the region: Lysva, Kungur, Berezniki, Kizel, Osa. Treatment of ulcer perforation and bleeding was accomplished at the department of surgical diseases of pediatric faculty, led by Professor V. N. Repin. He also developed vagotomy and methods of diagnostics and treatment of diseases of operated stomach. Comorbidity was also researched. The combination of liver and biliary tract diseases was researched in the Hospital surgical clinic of Perm, initially led by Professor S. Yu. Minkin and then by academician E. A. Wagner (L. F. Palatova). The results of surgical treatment of cholelithiasis, depending on morphological and biochemical abnormalities in liver and chemical composition of gallstones were studied (L. P. Kotelnikova). Indications for surgery in cholelithiasis in conjunction with pathology of stomach, duodenum and liver were defined (A. V. Popov). The results of surgical treatment of biliary pancreatitis and cholangitis (L. B. Guschensky), and diseases of stomach, duodenum and pancreas with cholelithiasis were obtained (D. V. Shvarev). Conclusion. The priority trends of research of Perm scientists were treatment of post-resection syndrome, arteriomesenterial obstruction, pathogenesis of gallstone disease and its combination with other disorders of the digestive system.

      1. История развития хирургии желудка в России в XIX-ХХ вв. / Д. А. Балалыкин М.: Медицина, 2005: ППП Тип. Наука - 318 с.
      2. Краткие исторические данные о клинике факультетской хирургии Пермского медицинского института // Фенелонов А. Л., Иванов И. А. / Труды научной историко-медицинской конференции Урало-Сибирских областей 1962 г. Вып. 2 Пермь, 1963 г. С. 121 - 127
      3. В городе М: очерки политической повседневности советской провинции в 40 - 50-х годах XX века / Олег Лейбович Пермь: Продюсерский центр «Июль-Медиа», 2009 - 437 с.
      4. Реконструктивно-восстановительные операции при язвенной болезни / / В. Н. Репин, А. В. Овечкин, М. В. Репин; М-во здравоохранения РФ. Перм. гос. мед. акад. Пермь, 1998 - 141 с.
      5. Опыт работы городского центра лечения больных с гастродуоденальными кровотечениями // Репин В. Н., Возгомент А. О., Чудинов А. А., Гудков О. С. / Актуальные проблемы абдоминальной хирургии Сборник научных работ, посвященный 20-летию кафедры хирургических болезней ПГМА (зав. Кафедрой - профессор В. Н. Репин) на базе МСЧ№ 9 им. М. А. Тверье г. Перми ЭИС ОЦНИТ ПГТУ 1999 с. 7 - 14
      6. Особенности клинического течения и лечение больных с сочетанной патологией пищеварительной системы // Дудченко М. А., Третьяк Н. Г., Сорокина С. И., Шевченко Т. И. / Мир медицины и биологии, вып. № 3, т7. 2011, с 1 - 6
     


    Full text is published :
    Palatova L.F., Nechaev O.I. DEVELOPMENT OF SURGICAL GASTROENTEROLOGY IN PRIKAMYE. Experimental and Clinical Gastroenterology Journal. 2016;129(05):88-92
    Read & Download full text